AU2003200679B2 - Transcriptional Activator LEC1 Nucleic Acids, Polypeptides and Their Use - Google Patents
Transcriptional Activator LEC1 Nucleic Acids, Polypeptides and Their Use Download PDFInfo
- Publication number
- AU2003200679B2 AU2003200679B2 AU2003200679A AU2003200679A AU2003200679B2 AU 2003200679 B2 AU2003200679 B2 AU 2003200679B2 AU 2003200679 A AU2003200679 A AU 2003200679A AU 2003200679 A AU2003200679 A AU 2003200679A AU 2003200679 B2 AU2003200679 B2 AU 2003200679B2
- Authority
- AU
- Australia
- Prior art keywords
- plant
- lec1
- polynucleotide
- plant cell
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims description 107
- 102000039446 nucleic acids Human genes 0.000 title claims description 103
- 108020004707 nucleic acids Proteins 0.000 title claims description 103
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 82
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 80
- 229920001184 polypeptide Polymers 0.000 title claims description 79
- 102100036791 Adhesion G protein-coupled receptor L2 Human genes 0.000 title claims 33
- 101000928189 Homo sapiens Adhesion G protein-coupled receptor L2 Proteins 0.000 title claims 33
- 108091006106 transcriptional activators Proteins 0.000 title description 14
- 241000196324 Embryophyta Species 0.000 claims description 273
- 238000000034 method Methods 0.000 claims description 190
- 108090000623 proteins and genes Proteins 0.000 claims description 140
- 102000040430 polynucleotide Human genes 0.000 claims description 131
- 108091033319 polynucleotide Proteins 0.000 claims description 131
- 239000002157 polynucleotide Substances 0.000 claims description 131
- 230000014509 gene expression Effects 0.000 claims description 116
- 230000009466 transformation Effects 0.000 claims description 87
- 102000004169 proteins and genes Human genes 0.000 claims description 79
- 240000008042 Zea mays Species 0.000 claims description 63
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 61
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 48
- 235000009973 maize Nutrition 0.000 claims description 48
- 230000009261 transgenic effect Effects 0.000 claims description 34
- 230000001965 increasing effect Effects 0.000 claims description 30
- 239000013598 vector Substances 0.000 claims description 30
- 210000001161 mammalian embryo Anatomy 0.000 claims description 28
- 230000012010 growth Effects 0.000 claims description 27
- 244000068988 Glycine max Species 0.000 claims description 25
- 235000010469 Glycine max Nutrition 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 25
- 235000021307 Triticum Nutrition 0.000 claims description 21
- 241000209140 Triticum Species 0.000 claims description 21
- 230000001939 inductive effect Effects 0.000 claims description 21
- 239000002363 auxin Substances 0.000 claims description 19
- 230000000392 somatic effect Effects 0.000 claims description 19
- 229930192334 Auxin Natural products 0.000 claims description 18
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 18
- 230000030118 somatic embryogenesis Effects 0.000 claims description 17
- 230000013020 embryo development Effects 0.000 claims description 15
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 13
- 235000005822 corn Nutrition 0.000 claims description 13
- 230000000692 anti-sense effect Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000011084 recovery Methods 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 9
- 230000001172 regenerating effect Effects 0.000 claims description 9
- 238000012357 Gap analysis Methods 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 241000219194 Arabidopsis Species 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 claims description 6
- 235000006008 Brassica napus var napus Nutrition 0.000 claims description 6
- 240000000385 Brassica napus var. napus Species 0.000 claims description 6
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 claims description 6
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 6
- 244000020551 Helianthus annuus Species 0.000 claims description 6
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 6
- 240000004658 Medicago sativa Species 0.000 claims description 6
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims description 6
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 6
- 240000007594 Oryza sativa Species 0.000 claims description 5
- 235000007164 Oryza sativa Nutrition 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 239000012092 media component Substances 0.000 claims description 5
- 235000009566 rice Nutrition 0.000 claims description 5
- 229920000742 Cotton Polymers 0.000 claims description 4
- 244000299507 Gossypium hirsutum Species 0.000 claims description 4
- 229920002477 rna polymer Polymers 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 240000006394 Sorghum bicolor Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 description 130
- 235000018102 proteins Nutrition 0.000 description 74
- 210000002257 embryonic structure Anatomy 0.000 description 72
- 239000002609 medium Substances 0.000 description 71
- 210000001519 tissue Anatomy 0.000 description 71
- 206010020649 Hyperkeratosis Diseases 0.000 description 67
- 108020004414 DNA Proteins 0.000 description 64
- 238000011282 treatment Methods 0.000 description 51
- 239000002299 complementary DNA Substances 0.000 description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 239000013612 plasmid Substances 0.000 description 33
- 239000005090 green fluorescent protein Substances 0.000 description 27
- 239000002245 particle Substances 0.000 description 26
- 230000008929 regeneration Effects 0.000 description 26
- 238000011069 regeneration method Methods 0.000 description 26
- 239000012634 fragment Substances 0.000 description 24
- 230000000408 embryogenic effect Effects 0.000 description 23
- 239000000203 mixture Substances 0.000 description 21
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 17
- 238000009396 hybridization Methods 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- 239000013615 primer Substances 0.000 description 16
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 241000589158 Agrobacterium Species 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000010367 cloning Methods 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 108091023040 Transcription factor Proteins 0.000 description 9
- 102000040945 Transcription factor Human genes 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 210000005069 ears Anatomy 0.000 description 9
- 239000004009 herbicide Substances 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 101100342815 Caenorhabditis elegans lec-1 gene Proteins 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
- 229910052737 gold Inorganic materials 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 7
- 101150080441 LEC1 gene Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000701489 Cauliflower mosaic virus Species 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 108091060211 Expressed sequence tag Proteins 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 240000005979 Hordeum vulgare Species 0.000 description 6
- 235000007340 Hordeum vulgare Nutrition 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 244000062793 Sorghum vulgare Species 0.000 description 6
- 102000002933 Thioredoxin Human genes 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000030279 gene silencing Effects 0.000 description 6
- 238000012226 gene silencing method Methods 0.000 description 6
- 230000002363 herbicidal effect Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000644 propagated effect Effects 0.000 description 6
- 210000001938 protoplast Anatomy 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000004114 suspension culture Methods 0.000 description 6
- 108060008226 thioredoxin Proteins 0.000 description 6
- 229940094937 thioredoxin Drugs 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108700001094 Plant Genes Proteins 0.000 description 5
- 108090000848 Ubiquitin Proteins 0.000 description 5
- 102000044159 Ubiquitin Human genes 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 230000035784 germination Effects 0.000 description 5
- 230000008774 maternal effect Effects 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000002689 soil Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 5
- 229910052721 tungsten Inorganic materials 0.000 description 5
- 239000010937 tungsten Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108010000700 Acetolactate synthase Proteins 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 4
- 241000209510 Liliopsida Species 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- OJOBTAOGJIWAGB-UHFFFAOYSA-N acetosyringone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1O OJOBTAOGJIWAGB-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000005014 ectopic expression Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 241001233957 eudicotyledons Species 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000004161 plant tissue culture Methods 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 description 4
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 229940023877 zeatin Drugs 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 108700027952 Arabidopsis LEC1 Proteins 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 101150103518 bar gene Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 108010002685 hygromycin-B kinase Proteins 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 239000011785 micronutrient Substances 0.000 description 3
- 235000013369 micronutrients Nutrition 0.000 description 3
- 235000019713 millet Nutrition 0.000 description 3
- 239000003147 molecular marker Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- -1 phosphoramidite triester Chemical class 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 229940063673 spermidine Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000005026 transcription initiation Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 241000533228 Argemone Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 240000001689 Cyanthillium cinereum Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000631948 Homo sapiens Sodium-dependent proline transporter Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102100028114 Sodium-dependent proline transporter Human genes 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 235000007244 Zea mays Nutrition 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 108010079058 casein hydrolysate Proteins 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000010154 cross-pollination Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000034373 developmental growth involved in morphogenesis Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000021759 endosperm development Effects 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 108010058731 nopaline synthase Proteins 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229930195732 phytohormone Natural products 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000014714 prickly poppy Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 108010008664 streptomycin 3''-kinase Proteins 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-DOMIDYPGSA-N 2-(2,4-dichlorophenoxy)acetic acid Chemical compound OC(=O)[14CH2]OC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-DOMIDYPGSA-N 0.000 description 1
- VDRACTHWBNITQP-UHFFFAOYSA-N 2-(3-methylbutyl)-7h-purin-6-amine Chemical compound CC(C)CCC1=NC(N)=C2NC=NC2=N1 VDRACTHWBNITQP-UHFFFAOYSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- PLUDYDNNASPOEE-UHFFFAOYSA-N 6-(aziridin-1-yl)-1h-pyrimidin-2-one Chemical compound C1=CNC(=O)N=C1N1CC1 PLUDYDNNASPOEE-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- 101150011812 AADAC gene Proteins 0.000 description 1
- 101150001232 ALS gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000406588 Amblyseius Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101710117679 Anthocyanidin 3-O-glucosyltransferase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 241001666768 Barce Species 0.000 description 1
- 241000724256 Brome mosaic virus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 239000005496 Chlorsulfuron Substances 0.000 description 1
- 108010061190 Cinnamyl-alcohol dehydrogenase Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000005504 Dicamba Substances 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000228138 Emericella Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 239000005980 Gibberellic acid Substances 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 101710095807 Glutelin-2 Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101710103773 Histone H2B Proteins 0.000 description 1
- 102100021639 Histone H2B type 1-K Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 241000235789 Hyperoartia Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 101100409013 Mesembryanthemum crystallinum PPD gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710196810 Non-specific lipid-transfer protein 2 Proteins 0.000 description 1
- 102100022201 Nuclear transcription factor Y subunit beta Human genes 0.000 description 1
- 101710205449 Nuclear transcription factor Y subunit beta Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 101710117029 Peroxisome proliferator-activated receptor delta Proteins 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 239000005595 Picloram Substances 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 244000082988 Secale cereale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 101150104425 T4 gene Proteins 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 241001414989 Thysanoptera Species 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000003302 UV-light treatment Methods 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 230000009418 agronomic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 235000020415 coconut juice Nutrition 0.000 description 1
- 230000008645 cold stress Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012297 crystallization seed Substances 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- IWEDIXLBFLAXBO-UHFFFAOYSA-N dicamba Chemical compound COC1=C(Cl)C=CC(Cl)=C1C(O)=O IWEDIXLBFLAXBO-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 1
- IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- JTEDVYBZBROSJT-UHFFFAOYSA-N indole-3-butyric acid Chemical compound C1=CC=C2C(CCCC(=O)O)=CNC2=C1 JTEDVYBZBROSJT-UHFFFAOYSA-N 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 1
- 229960001669 kinetin Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000006870 ms-medium Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000009401 outcrossing Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 101150113864 pat gene Proteins 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003415 peat Substances 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- NQQVFXUMIDALNH-UHFFFAOYSA-N picloram Chemical compound NC1=C(Cl)C(Cl)=NC(C(O)=O)=C1Cl NQQVFXUMIDALNH-UHFFFAOYSA-N 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 101150063097 ppdK gene Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009576 somatic growth Effects 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000006918 subunit interaction Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HNJXPTMEWIVQQM-UHFFFAOYSA-M triethyl(hexadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](CC)(CC)CC HNJXPTMEWIVQQM-UHFFFAOYSA-M 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000009105 vegetative growth Effects 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Description
I S&F Ref: 55346CD
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT
ORIGINAL
Name and Address of Applicants: E.I. Du Pont De Nemours Co.
1007 Market Street, Suite 9000 Du Pont Building Wilmington Delaware 19898 United States of America Pioneer Hi-Bred International, Inc.
800 Capital Square, 400 Locust Street Des Moines Iowa 50309 United States of America Actual Inventor(s): Address for Service: Invention Title: Keith S. Lowe, William J. Gordon-Kamm, Theodore M.
Klein, Sonriza Rasco-Gaunt, Rebecca E. Cahoon, Xifan Sun, George J. Hoerster, Carolyn Ann Gregory, Ramgopal Nadimpalli Spruson Ferguson St Martins Tower,Level 31 Market Street Sydney NSW 2000 (CCN 3710000177) Transcriptional Activator LEC1 Nucleic Acids, Polypeptides and Their Use The following statement is a full description of this invention, including the best method of performing it known to me/us:- 5845c TRANSCRIPTIONAL ACTIVATOR LEC1 NUCLEIC ACIDS, POLYPEPTIDES AND THEIR USES TECHNICAL FIELD The present invention relates generally to plant molecular biology. More specifically, it relates to nucleic acids and methods for modulating their expression in plants.
BACKGROUND OF THE INVENTION Major advances in plant transformation have occurred over the last few years. However, in major crop plants, such as maize and soybeans, serious genotype limitations still exist. Transformation of agronomically important maize inbred lines continues to be both difficult and time consuming. Traditionally, the only way to elicit a culture response has been by optimizing medium components and/or explant material and source. This has led to success in some genotypes, but most elite hybrids fail to produce a favorable culture response. While, transformation of model genotypes is efficient, the process of introgressing transgenes into production inbreds is laborious, expensive and time consuming.
It would save considerable time and money if genes could be introduced into and evaluated directly in commercial hybrids.
Current methods for genetic engineering in maize require a specific cell type as the recipient of new DNA. These cells are found in relatively undifferentiated, rapidly growing callus cells or on the scutellar surface of the immature embryo (which gives rise to callus). Irrespective of the delivery method currently used, DNA is introduced into literally thousands of cells, yet transformants are recovered at frequencies of 10s relative to transientlyexpressing cells. Exacerbating this problem, the trauma that accompanies DNA introduction directs recipient cells into cell cycle arrest and accumulating evidence suggests that many of these cells are directed into apoptosis or programmed cell death. (Reference Bowen et al, Third International Congress of the International Society for Plant Molecular Biology, 1991, Abstract 1093).
Therefore it would be desirable to provide improved methods capable of increasing transformation efficiency in a number of cell types.
Typically a selectable marker is used to recover transformed cells.
Traditional selection schemes expose all cells to a phytotoxic agent and rely on the introduction of a resistance gene to recover transformants. Unfortunately, the presence of dying cells may reduce the efficiency of stable transformation. It would therefore be useful to provide a positive selection system for recovering transformants.
In spite of increases in yield and harvested area worldwide, it is predicted that over the next ten years, meeting the demand for corn will require an additional 20% increase over current production (Dowswell, Paliwal, R.L., Cantrell, 1996, Maize in the Third World, Westview Press, Boulder, CO).
In hybrid crops, including grains, oil seeds, forages, fruits and vegetables, there are problems associated with the development and production of hybrid seeds. The process of cross-pollination of plants is laborious and expensive. In the cross-pollination process, the female plant must be prevented from being fertilized by its own pollen. Many methods have been developed over the years, such as detasseling in the case of corn, developing and maintaining male sterile lines, and developing plants that are incompatible with their own pollen, to name a few. Since hybrids do not breed true, the process must be repeated for the production of every hybrid seed lot.
To further complicate the process, inbred lines are crossed. For example in the case of corn, the inbreds can be low yielding. This provides a major challenge in the production of hybrid seed corn. In fact, certain hybrids cannot be commercialized at all due to the performance of the inbred lines. The production of hybrid seeds is consequently expensive, time consuming and provides known and unknown risks. It would therefore be valuable to develop new methods which contribute to the increase of production efficiency of hybrid seed.
As new traits are added to commercial crops by means of genetic engineering, problems arise in "stacking" traits. In order to develop heritable stacked traits, the traits must be linked because of segregating populations.
Improved methods for developing hybrid seed which would not require linking of the traits would significantly shorten the time for developing commercial hybrid seeds.
I
Gene silencing is another problem in developing heritable traits with genetic engineering. Frequently gene silencing is seen following meiotic divisions. Elimination or reduction of this problem would advance the state of science and industry in this area.
SUMMARY OF THE INVENTION It is the object of the present invention to provide nucleic acids and polypeptides relating to embryogenesis.
It is another object of the present invention-4o provide nucleic acids and polypeptides that can be used to identify interacting proteins involved in transcription regulation in embryogenesis.
It is another object of the present invention to provide antigenic fragments of the polypeptides of the present invention.
It is another object of the present invention to provide transgenic plants and plant parts containing the nucleic acids of the present invention.
It is another object of the present invention to provide methods for modulating, in a transgenic plant, the expression of the nucleic acids of the present invention.
It is another object of the present invention to provide a method for improving transformation frequencies.
It is another object of the present invention to provide a method for improving transformation efficiency in cells from various sources.
It is another object of the present invention to provide a method for a positive selection system.
It is another object of the present invention to provide a method for efficiently producing hybrid seed via apomixis.
It is another object of the present invention to provide a method for stacking traits which does not require linking of traits.
It is another object of the present invention to provide a method for reducing the problem of gene silencing.
There is herein disclosed a HAP3-type CCAAT-box binding transcriptional activator polynucleotides and polypeptides, and in particular, the leafy cotyledon 1 transcriptional activator (LEC 1) polynucleotides and I I polypeptides. There is further disclosed herein expression cassettes optionally linked in antisense orientation, host cells transfected with at least one expression cassette, and transgenic plants and seeds comprising the expression cassettes. There is further disclosed herein methods of using the polynucleotides and polypeptides. In a further aspect, the present invention relates to a method of modulating expression of the polynucleotides encoding the polypeptides of the present invention in a plant. Expression of the polynucleotides encoding the proteins disclosed herein can be increased or decreased relative to a non-transformed control plant.
According to a first embodiment of the invention, there is provided a Led isolated nucleic acid comprising a member selected from the group consisting of: a polynucleotide which encodes a polypeptide of SEQ ID NO:22; a polynucleotide having at least 75% sequence identity to SEQ ID NO:21, wherein the sequence identity is based on the entire sequence and is determined by GAP analysis using Gap Weight of 50 and Length Weight of 3; a polynucleotide having the sequence set forth in SEQ ID NO:21; and a polynucleotide complementary to a polynucleotide of(a) through According to a second embodiment of the invention, there is provided a vector comprising at least one nucleic acid in accordance with the first embodiment of the present invention.
According to a third embodiment of the invention, there is provided an expression cassette comprising at least one nucleic acid in accordance with the first embodiment of the present invention, operably linked to a promoter, wherein the nucleic acid is in sense or antisense orientation.
According to a fourth embodiment of the invention, there is provided a plant cell containing at least one isolated nucleic acid in accordance with the first embodiment of the present invention.
According to a fifth embodiment of the invention, there is provided a Led isolated protein comprising a member selected from the group consisting of: a polypeptide comprising at least 75% sequence identity to SEQ ID NO:22, wherein the sequence identity is determined by GAP analysis using Gap Weight of 12 and Length Weight of 4; a polypeptide encoded by a nucleic acid in accordance with the first embodiment of the present invention; a polypeptide encoded by a nucleic acid of SEQ ID NO:21; and a polypeptide having the sequence set forth in SEQ ID NO:22.
[I:\DayLib\LIBFF]72650specdoc:gcc 4a According to a sixth embodiment of the invention, there is provided a ribonucleic acid sequence encoding a protein in accordance with the fifth embodiment of the present invention.
According to a seventh embodiment of the invention, there is provided a method for s modulating LECI activity in a plant, comprising: transforming a plant cell with at least one expression cassette in accordance with the third embodiment of the present invention and regenerating a transformed plant that expresses the at least one nucleic acid in an amount sufficient to modulate LECI activity in the plant.
According to an eighth embodiment of the invention, there is provided a method for transiently modulating the level of LEC 1 activity in plant cells comprising introducing at least one nucleic acid in accordance with the first embodiment of the present invention.
According to a ninth embodiment of the invention, there is provided a method for transiently modulating the level of LEC 1 activity in plant cells comprising introducing at least one polypeptide in accordance with the fifth embodiment of the present invention.
According to a tenth embodiment of the invention, there is provided a method for enhancing tissue culture response in a plant cell comprising introducing into the plant cell at least one LEC1 polypeptide or at least one LEC1 polynucleotide under conditions sufficient to enhance tissue culture response.
According to an eleventh embodiment of the invention, there is provided a method for inducing somatic embryogenesis in a plant cell comprising introducing into a responsive plant cell at least one LEC1 polypeptide or at least one LEC1 polynucleotide, wherein the responsive plant cell is transformed and grown under conditions sufficient to stimulate the production of a transformed embryo and wherein the plant cell is other than an Arabidopsis cell.
According to a twelfth embodiment of the invention, there is provided a method for positive selection of a transformed cell comprising introducing into a responsive plant cell at least one LECI polynucleotide or at least one LEC1 polypeptide and growing the transformed plant cell, wherein the responsive plant cell is transformed and grown under conditions sufficient to induce embryogenesis to provide a positive selection means.
According to a thirteenth embodiment of the invention, there is provided a method for inducing apomixis in a plant cell comprising introducing into a responsive plant cell at least one LECI polypeptide or at least one LEC 1 polynucleotide and growing the plant I:\DayLib\LIBFF]72650spec.doc:gcc 4b cell, wherein the introducing and growing is done under conditions sufficient to produce a transformed somatic embryo.
According to a fourteenth embodiment of the invention, there is provided a plant produced by the method in accordance with the thirteenth embodiment of the present invention.
According to a fifteenth embodiment of the invention, there is provided a method for increasing transformation efficiency comprising introducing at least one LEC1 polypeptide or at least one LECI polynucleotide into a responsive plant cell under conditions sufficient to increase transformation efficiency.
to According to a sixteenth embodiment of the invention, there is provided a method for increasing recovery of regenerated plants comprising introducing into a responsive plant cell at least one LEC1 polypeptide or at least one LEC1 polynucleotide and growing the plant cell, wherein the introducing and growing are under conditions sufficient to produce a regenerated plant.
Brief Description of the Drawing Figure 1 depicts the comparison of various sequences and the alignment of the conserved regions.
Detailed Description of the Invention Definitions The term "isolated" refers to material, such as a nucleic acid or a protein, which is: substantially or essentially free from components which normally accompany or interact with the material as found in its naturally occurring environment or if the material is in its natural environment, the material has been altered by deliberate human intervention to a composition and/or placed at a locus in the cell other than the locus native to the material.
As used herein, "nucleic acid" means a polynucleotide and includes single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases. Nucleic acids may also include modified nucleotides that permit correct read through by a polymerase and do not alter the expression of a polypeptide encoded by the polynucleotide.
As used herein, "LEC1 nucleic acid" means a nucleic acid or polynucleotide that codes for a LEC1 polypeptide.
[I:\DayLib\LIBFF]72650spec.doc:gcc 4c As used herein, "polypeptide" means proteins, protein fragments, modified proteins, amino acid sequences and synthetic amino acid sequences. The polypeptide can be glycosylated or not.
[l:\DayLib\LB FF]72650spec.doc:gcc _I As used herein, "LECI polypeptide" means a HAP3 family member, CCAAT-box binding transcriptional activator polypeptide that regulates gene expression during embryo development, and that contains the conserved sequence set out in SEQ ID NO: 23.
As used herein, "plant" includes plants and plant parts including but not limited to plant cells, plant tissue such as leaves, stems, roots, flowers, and seeds.
As used herein, "promoter" includes reference to a region of DNA upstream from the start of transcription and involved in recognition and binding of RNA polymerase and other proteins to initiate transcription.
By "fragment" is intended a portion of the nudeotide sequence or a portion of the amino acid sequence and hence protein encoded thereby. Fragments of a nucteotide sequence may encode protein fragments that retain the biological activity of the native nucleic acid. Alternatively, fragments of a nucleotide sequence that are useful as hybridization probes generally do not encode fragment proteins retaining biological activity. Thus, fragments of a nucleotide sequence are generally greater than 20, 30, 50, 100, 150, 200 or 300 nucleotides and up to the entire nucleotide sequence encoding the proteins of the invention.
Generally the probes are less than 1000 nucleotides and preferably less than 500 nucleotides. Fragments of the invention include antisense sequences used to decrease expression of the inventive polynucleotides. Such antisense fragments may vary in length ranging from at least about 20 nucleotides, about nucleotides, about 100 nucleotides, up to and including the entire coding.
sequence.
By ufunctional equivalent" as applied to a polynucleotide or a protein is intended a polynucleotide or a protein of sufficient length to modulate the level of LEC1 protein activity in a plant cell. A polynucleotide functional equivalent can be in sense or antisense orientation.
By "variants" is intended substantially similar sequences. Generally, nucleic acid sequence variants of the invention will have at least 60%, 65%, or preferably 75%, 80% or 90%, more preferably at least 95% and most preferably at least 98% sequence identity to the native nucleotide sequence, wherein the sequence identity is based on the entire sequence and is I I -6determined by GAP analysis using Gap Weight of 50 and Length Weight of 3.
Generally, polypeptide sequence variants of the invention will have at least about 55%, 60%, 65%, 70%, 75% or 80%, preferably at least about 85% or and more preferably at least about 95% sequence identity to the native protein, wherein the sequence identity is based on the entire sequence and is determined by GAP analysis using Gap Weight of 12 and Length Weight of 4.
A "responsive plant cell" or "responsive host cell" refers to a cell that exhibits a positive response to the introduction of LEC1 polypeptide or LEC1 polynucleotide compared to a cell that has not been introduced with LEC1 polypeptide or LEC1 polynucleotide. The response can be to enhance tissue culture response, induce somatic embryogenesis, induce apomixis, increase transformation efficiency or increase recovery of regenerated plants: A "recalcitrant plant cell" is a responsive plant cell that generally does not exhibit a positive response such as tissue culture response, transformation efficiency or recovery of regenerated plants.
NUCLEIC ACIDS The present invention relates to a HAP3-type CCAAT-box binding transcriptional activators, and in particular, the leafy cotyledon 1 transcriptional activator (LEC1). Expression of the LEC1 polynucleotide initiates formation of embryo-like structures and improves growth and recovery of transformants. The term apomixis is used to describe asexual reproduction that replaces or substitutes sexual methods of reproduction. When apomixis occurs, embryos are produced from maternal tissue and use only the maternal genome.
There is herein disclosed an isolated nucleic acid comprising a member selected from the group consisting of: a polynucleotide which encodes a polypeptide of SEQ ID NO: 2, 8, 12, 14, 16, 18, 20, or 22; a polynucleotide amplified from a plant nucleic acid library using the primers of SEQ ID NOS: 3 and 4, 5 and 6, 9 and 10, or 11 and 12 or primers determined by using Vector nti Suite, InforMax Version a polynucleotide comprising at least 20 contiguous bases of SEQ ID NO: 1, 7, 9, 11, 13, 15, 17, 19, or21; I I a polynucleotide encoding a plant HAP3-type ccaat-box transcriptional activator with the conserved motif of SEQ ID NO: 23, wherein the polynudeotide is from a plant other than Arabidopsis; a polynudeotide having at least 60% sequence identity to SEQ ID NO: 1, 9,11,13,17, or 21 or 65% sequence identity to SEQ ID NO: 15 or 19 or 70% sequence identity to SEQ ID NO: 7, wherein the sequence identity is based on the entire sequence and is determined by GAP analysis using Gap Weight of 50 and Length Weight of 3; a polynucleotide comprising at least 25 nucleotides in length which hybridizes under high stringency conditions to a polynucleotide having the sequence set forth in SEQ ID NO: 1, 7, 9, 11, 13, 15, 17, 19, or 21; a polynucleotide encoding the protein of SEQ ID NO: 2, 8, 10, 12, 14, 16, 18, 20, or 22, wherein the polynucleotide is from a plant other than Arabidopsis; a polynucleotide having the sequence set forth in SEQ ID NO: 1,7, 9, 11, 13,15,17,19, or21; and a polynucleotide complementary to a polynucleotide of through In many cases of apomixis maternal tissues such as the nucellus or inner integument "bud off producing somatic embryos. These embryos then develop normally into seed. Since meiosis and fertilization are circumvented, the plants developing from such seed are genetically identical to the maternal plant.
Expression of the leafy cotyledon 1 gene in the nucellus integument, or cell specific expression in the megaspore mother cell would trigger embryo formation from maternal tissues.
Producing a seed identical to the parent has many advantages. For example high yielding hybrids could be used in seed production to multiply identical copies of high yielding hybrid seed. This would greatly reduce seed cost as well as increase the number of genotypes which are commercially available.
Genes can be evaluated directly in commercial hybrids since the progeny would not segregate. This would save years of back crossing.
Apomixis would also provide a method of containment of transgenes when coupled with male sterility. The construction of male sterile autonomous agamospermy would prevent genetically engineered traits from hybridizing with weedy relatives.
Gene stacking would be relatively easy with apomixis. Hybrids could be successively re-transformed with various new traits and propagated via apomixis.
The traits would not need to be linked since apomixis avoids the problems associated with segregation.
Apomixis can provide a reduction in gene silencing. Gene silencing is frequently seen following meiotic divisions. Since meiotic divisions never occur, it may be possible to eliminate or reduce the frequency of gene silencing. Apomixis can also be used stabilize desirable phenotypes with complex traits such as hybrid vigor. Such traits could easily be maintained and multiplied indefinitely via apomixis.
The Cauliflower Mosaic Virus 35S promoter has been used to overexpress LEC1 during Agrobacterium-mediated in planta transformation of Arabidopsis (Harada et al., WO 98/37184). As pointed out by Harada et al., 35S is a strong promoter, and in their experiments it was found that 35S:LEC1 did not improve transformation and actually appeared to hinder it (transformation efficiency with 35S:LEC1 was estimated to be 0.6% of that obtained normally). Thus, overexpression in a cell type such as those in the gametophytic stage of development may be inappropriate and detrimental to the transformation process and successful recovery of transformed progeny. In contrast, we have shown that ectopic expression of the LEC1 gene under the appropriate control elements (including tissue specific and/or inducible promoters) and in the appropriate plant cells can be used to stimulate embryo formation in tissues/genotypes normally not amenable to culture. Likewise ectopic expression in genotypes amenable to culture can increase the number of embryo precursor cells (or increase the number that develop into embryos) leading to an increase in transformation frequency. Transient expression using RNA or protein may be sufficient to initiate the cascade of events leading to embryo formation. This would be valuable in such target tissues as maize scutella, immature leaf bases, immature tassels, etc.
The LEC1 gene could be used as a positive selectable marker, i.e. triggering I I embryogenesis in transgenic cells without killing the surrounding wild-type cells.
This would happen since the cells receiving the introduced gene would undergo embryogenesis or in tissues already undergoing embryogenesis LEC1 expression would stimulate more rapid reiteration of somatic embryos.
It has been shown through sequence similarity that the Arabidopsis LEC1 polypeptide is homologous to the HAP3 subunit of the "CCAAT-box binding factor class of eukaryotic transcriptional activators (Lotan et al., 1998, Cell 93:1195-1205). This class of proteins, which consist of Hap2/3/4 and 5, form a heteroligomeric transcriptional complex, that appears to activate specific gene sets in eukaryotes. Certain members of this family such as Hap2 and HapS appear to be ubiquitously expressed, while different Hap3 members are under developmental or environmental regulation. Plant HAP3 polypeptides can be recognized by a high degree of sequence identity to other HAP3 homologs in the "B domain" of the protein. For example, the B domain for the Arabidopsis LEC1, from amino acid residue 28 to residue 117, shares between 55% and 63% identity (75-85% similarity) to other members of the HAP3 family, including maize (HAP3), chicken, lamprey, Xenopus, human, mouse, Emericella nidulens, Schizosaccharomyces pombe, Saccharomyces cerevisiae and Kluuyveromyces lactis (Lotan et al., 1998).
Expression of the LEC1 gene in transformed cells initiates embryo development and stimulates development of pre-existing embryos. Normally, LEC1 expression is necessary for proper embryo maturation in the latter stages of embryo development, and LECi transgene expression thus may also promote these processes. The combined effect of these impacts on somatic embryogenesis is not only to stimulate growth of transformed cells, but also to insure that transformed somatic embryos develop in a normal, viable fashion (increasing the capacity of transformed somatic embryos to germinate vigorously).
Continued ectopic overexpression beyond embryo maturation may negatively impact germination and vegetative plant growth (which may necessitate downregulation of the LEC1 transgene during these stages of development.
Expression of the LEC1 gene will stimulate growth in cells with the potential to initiate or maintain embryogenic growth. Cells in established meristems or meristem-derive cell lineages may be less prone to undergo the
I
transition to embryos. In addition, transformation methods that target certain reproductive tissues (or cells) such as vacuum-infiltration of Agrobacterium into Arabidopsis may have detrimental effects on recovery of transformants (triggering genes associated with embryogenesis may disrupt the proper functioning of these cells).
The polypeptides encoded by the present plant LEC1 genes can be distinguished from non-LEC HAP3 proteins by using the diagnostic motif shown in SEQ ID NO: 23.
The isolated nucleic acids of the present invention can be made using (a) standard recombinant methods, synthetic techniques, or combinations thereof.
In some embodiments, the polynucleotides of the present invention will be cloned, amplified, or otherwise constructed from a monocot or dicot. In preferred embodiments the monocot is corn, sorghum, barley, wheat, millet, or rice.
Preferred dicots include soybeans, sunflower, canola, alfalfa, potato, or cassava.
Functional fragments included in the invention can be obtained using primers which selectively hybridize under stringent conditions. Primers are generally at least 12 bases in length and can be as high as 200 bases, but will generally be from 15 to 75, preferably from 15 to 50. Functional fragments can be identified using a variety of techniques such as restriction analysis, Southern analysis, primer extension analysis, and DNA sequence analysis.
The present invention includes a plurality of polynucleotides that encode for the identical amino acid sequence. The degeneracy of the genetic code allows for such "silent variations" which can be used, for example, to selectively hybridize and detect allelic variants of polynucleotides of the present invention.
Additionally, the present invention includes isolated nucleic acids comprising allelic variants. The term "allele" as used herein refers to a related nucleic acid of the same gene.
Variants of nucleic acids included in the invention can be obtained, for example, by oligonucleotide-directed mutagenesis, linker-scanning mutagenesis, mutagenesis using the polymerase chain reaction, and the like. See, for example, Ausubel, pages 8.0.3 8.5.9. Also, see generally, McPherson DIRECTED MUTAGENESIS: A Practical Approach, (IRL Press, 1991). Thus, the present
I
-11invention also encompasses DNA molecules comprising nucleotide sequences that have substantial sequence similarity with the inventive sequences.
Variants included in the invention may contain individual substitutions, deletions or additions to the nucleic acid or polypeptide sequences which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid.
When the nucleic acid is prepared or altered synthetically, advantage can be taken of known codon preferences of the intended host.
The present invention also includes "shufflents" produced by sequence shuffling of the inventive polynucleotides to obtain a desired characteristic.
Sequence shuffling is described in PCT publication No. 96119256. See also, Zhang, J. et al., Proc. Natl. Acad. Sci. USA 94:4504-4509 (1997).
The present invention also includes the use of 5' and/or 3' UTR regions for modulation of translation of heterologous coding sequences. Positive sequence motifs include translational initiation consensus sequences (Kozak, Nucleic Acids Res. 15:8125 (1987)) and the 7-methylguanosine cap structure (Drummond et al., Nucleic Acids Res. 13:7375 (1985)). Negative elements include stable intramolecular 5' UTR stem-loop structures (Muesing et al., Cell 48:691 (1987)) and AUG sequences or short open reading frames preceded by an appropriate AUG in the 5' UTR (Kozak, supra, Rao et at, Mol. and Cell. Biol. 8:284 (1988)).
Further, the polypeptide-encoding segments of the polynucleotides of the present invention can be modified to alter codon usage. Altered codon usage can be employed to alter translational efficiency. Codon usage in the coding regions of the polynucleotides of the present invention can be analyzed statistically using commercially available software packages such as "Codon Preference" available from the University of Wisconsin Genetics Computer Group (see Devereaux et a., Nucleic Acids Res. 12:387-395 (1984)) or MacVector 4.1 (Eastman Kodak Co., New Haven, Conn.).
For example, the inventive nucleic acids can be optimized for enhanced expression in plants of interest. See, for example, EPA0359472; W091/16432; Perlak et al. (1991) Proc. Natl. Acad. Sci. USA 88:3324-3328; and Murray et al.
(1989) Nucleic Acids Res. 17:477-498. In this manner, the polynucleotides can
I
-12be synthesized utilizing plant-preferred codons. See, for example, Murray et al.
(1989) Nucleic Acids Res. 17:477-498, the disclosure of which is incorporated herein by reference.
The present invention provides subsequences comprising isolated nucleic acids containing at least 16 contiguous bases of the inventive sequences. For example the isolated nucleic acid includes those comprising at least 16, 20, 40, 50, 60, 75 or 100 contiguous nucleotides of the inventive sequences.
Subsequences of the isolated nucleic acid can be used to modulate or detect gene expression by introducing into the subsequences compounds which bind, intercalate, cleave and/or crosslink to nucleic acids.
The nucleic acids of the invention may conveniently comprise a multicloning site comprising one or more endonuclease restriction sites inserted into the nucleic acid to aid in isolation of the polynucleotide. Also, translatable sequences may be inserted to aid in the isolation of the translated polynucleotide of the present invention. For example, a hexa-histidine marker sequence provides a convenient means to purify the proteins of the present invention.
A polynucleotide of the present invention can be attached to a vector, adapter, promoter, transit peptide or linker for cloning and/or expression of a polynucleotide of the present invention. Additional sequences may be added to such cloning and/or expression sequences to optimize their function in cloning and/or expression, to aid in isolation of the polynucleotide, or to improve the introduction of the polynucleotide into a cell. Use of cloning vectors, expression vectors, adapters, and linkers is well known and extensively described in the art.
For a description of such nucleic acids see, for example, Stratagene Cloning Systems, Catalogs 1995, 1996, 1997 (La Jolla, CA); and, Amersham Life Sciences, Inc, Catalog '97 (Arlington Heights, IL).
The isolated nucleic acid compositions of this invention, such as RNA, cDNA, genomic DNA, or a hybrid thereof, can be obtained from plant biological sources using any number of cloning methodologies known to those of skill in the art. In some embodiments, oligonucleotide probes which selectively hybridize, under stringent conditions, to the polynucleotides of the present invention are used to identify the desired sequence in a cDNA or genomic DNA library.
II I Exemplary total RNA and mRNA isolation protocols are described in Plant Molecular Biology: A Laboratory Manual, Clark, Ed., Springer-Verlag, Berlin (1997); and, Current Protocols in Molecular Biology, Ausubel, et al., Eds., Greene Publishing and Wiley-lnterscience, New York (1995). Total RNA and mRNA isolation kits are commercially available from vendors such as Stratagene (La Jolla, CA), Clonetech (Palo Alto, CA), Pharmacia (Piscataway, NJ), and 5'-3' (Paoli, PA). See also, U.S. Patent Nos. 5,614,391; and, 5,459,253.
Typical cDNA synthesis protocols are well known to the skilled artisan and are described in such standard references as: Plant Molecular Biology: A Laboratory Manual, Clark, Ed., Springer-Verlag, Berlin (1997); and, Current Protocols in Molecular Biology, Ausubel, et al., Eds., Greene Publishing and Wiley-lnterscience, New York (1995). cDNA synthesis kits are available from a variety of commercial vendors such as Stratagene or Pharmacia.
An exemplary method of constructing a greater than 95% pure full-length cDNA library is described by Caminci et al., Genomics, 37:327-336 (1996). Other methods for producing full-length libraries are known in the art. See, Edery et al., Mol. Cell Biol. 15(6):3363-3371 (1995); and PCT Application WO 96/34981.
It is often convenient to normalize a cDNA library to create a library in which each clone is more equally represented. A number of approaches to normalize cDNA libraries are known in the art. Construction of normalized libraries is described in Ko, Nud. Acids. Res. 18(19):5705-5711 (1990); Patanjali et al., Proc. Natl. Acad. U.S.A. 88:1943-1947 (1991); U.S. Patents 5,482,685 and 5,637,685; and Soares et Proc. Natl. Acad. Sci. USA 91:9228-9232 (1994).
Subtracted cDNA libraries are another means to increase the proportion of less abundant cDNA species. See, Foote et al. in, Plant Molecular Biology: A Laboratory Manual, Clark, Ed., Springer-Verlag, Berlin (1997); Kho and Zarbl, Technique 3(2):58-63 (1991); Sive and St. John, Nucl. Acids Res. 16(22):10937 (1988); Current Protocols in Molecular Biology, Ausubel, et al., Eds., Greene Publishing and Wiley-lnterscience, New York (1995); and, Swaroop et al., Nucl.
Acids Res. 19(8):1954 (1991). cDNA subtraction kits are commercially available.
See, PCR-Select (Clontech).
To construct genomic libraries, large segments of genomic DNA are generated by random fragmentation. Examples of appropriate molecular
I
I
-14biological techniques and instructions are found in Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Vols. 1-3 (1989), Methods in Enzymology, Vol. 152: Guide to Molecular Cloning Techniques, Berger and Kimmel, Eds., San Diego: Academic Press, Inc. (1987), Current Protocols in Molecular Biology, Ausubel, et al., Eds., Greene Publishing and Wiley-lnterscience, New York (1995); Plant Molecular Biology: A Laboratory Manual, Clark, Ed., Springer-Verlag, Berlin (1997). Kits for construction of genomic libraries are also commercially available.
The cDNA or genomic library can be screened using a probe based upon the sequence of a nucleic acid of the present invention such as those disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous polynucleotides in the same or different plant species.
Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. The degree of stringency can be controlled by temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide.
Typically, stringent hybridization conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes 10 to 50 nucleotides) and at least about for long probes greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
For purposes of defining the invention the following conditions are provided. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCI, 1% SDS (sodium dodecyl sulfate) at 37°C, and a wash in iX to 2X SSC (20X SSC 3.0 M NaCI/0.3 M trisodium citrate) at 50°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1 M NaCI, 1% SDS at 37°C, and a wash in 0.5X to 1X SSC at 55°C. Exemplary high stringency conditions include hybridization in formamide, 1 M NaCI, 1% SDS at 37°C, and a wash in 0.1X SSC at Typically the time of hybridization is from 4 to 16 hours.
II I An extensive guide to the hybridization of nucleic acids is found in Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York (1993); and Current Protocols in Molecular Biology, Chapter 2, Ausubel, et al., Eds., Greene Publishing and Wiley-lnterscience, New York (1995). Often, cDNA libraries will be normalized to increase the representation of relatively rare cDNAs.
The nucleic acids of the invention can be amplified from nucleic acid samples using amplification techniques. For instance, polymerase chain reaction (PCR) technology can be used to amplify the sequences of polynucleotides of the present invention and related polynucleotides directly from genomic DNA or cDNA libraries. PCR and other in vitro amplification methods may also be useful, for example, to clone nucleic acid sequences.that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes.
Examples of techniques useful for in vitro amplification methods are found in Berger, Sambrook, and Ausubel, as well as Mullis et ak, U.S. Patent No.
4,683,202 (1987); and, PCR Protocols A Guide to Methods and Applications, Innis et al., Eds., Academic Press Inc., San Diego, CA (1990). Commercially available kits for genomic PCR amplification are known in the art. See, Advantage-GC Genomic PCR Kit (Clontech). The T4 gene 32 protein (Boehringer Mannheim) can be used to improve yield of long PCR products. PCR-based screening methods have also been described. Wilfinger et al. describe a PCR-based method in which the longest cDNA is identified in the first step so that incomplete clones can be eliminated from study. BioTechniques, 22(3):481486 (1997).
In one aspect of the invention, nucleic acids can be amplified from a plant nucleic acid library. The nucleic acid library may be a cDNA library, a genomic library, or a library generally constructed from nuclear transcripts at any stage of intron processing. Libraries can be made from a variety of plant tissues. Good results have been obtained using mitotically active tissues such as shoot meristems, shoot meristem cultures, embryos, callus and suspension cultures, immature ears and tassels, and young seedlings. The cDNAs of the present
I
invention were obtained from immature zygotic embryo and regenerating callus libraries.
Alternatively, the sequences of the invention can be used to isolate corresponding sequences in other organisms, particularly other plants, more particularly, other monocots. In this manner, methods such as PCR, hybridization, and the like can be used to identify such sequences having substantial sequence similarity to the sequences of the invention. See, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). and Innis et al.
(1990), PCR Protocols: A Guide to Methods and Applications (Academic Press, New York). Coding sequences isolated based on their sequence identity to the entire inventive coding sequences set forth herein or to fragments thereof are encompassed by the present invention.
The isolated nucleic acids of the present invention can also be prepared by direct chemical synthesis by methods such as the phosphotriester method of Narang et al., Meth. Enzymol. 68:90-99 (1979); the phosphodiester method of Brown et al., Meth. Enzymol. 68:109-151 (1979); the diethylphosphoramidite method of Beaucage et al, Tetra. Lett. 22:1859-1862 (1981); the solid phase phosphoramidite triester method described by Beaucage and Caruthers, Tetra.
Letts. 22(20):1859-1862 (1981), using an automated synthesizer, as described in Needham-VanDevanter et al., Nucleic Acids Res. 12:6159-6168 (1984); and, the solid support method of U.S. Patent No. 4,458,066. Chemical synthesis generally produces a single stranded oligonucleotide. This may be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill will recognize that while chemical synthesis of DNA is limited to sequences of about 100 bases, longer sequences may be obtained by the ligation of shorter sequences.
The nucleic acids of the present invention include those amplified using the following primer pairs: SEQ ID NOS: 3 and 4, 5 and 6, 9 and 10, or 11 and 12 or primers determined by using Vector nti Suite, InforMax Version
I
-17- EXPRESSION CASSETTES In another embodiment expression cassettes comprising isolated nucleic acids of the present invention are provided. An expression cassette will typically comprise a polynucleotide of the present invention operably linked to transcriptional initiation regulatory sequences which will direct the transcription of the polynucleotide in the intended host cell, such as tissues of a transformed plant.
The construction of such expression cassettes which can be employed in conjunction with the present invention is well known to those of skill in the art in light of the present disclosure. See, Sambrook, et Molecular Cloning: A Laboratory Manual; Cold Spring Harbor, New York; (1989); Gelvin, et Plant Molecular Biology Manual (1990); Plant Biotechnology: Commercial Prospects and Problems, eds. Prakash, etal; Oxford IBH Publishing Co.; New Delhi, India; (1993); and Heslot, et al.; Molecular Biology and Genetic Engineering of Yeasts; CRC Press, Inc., USA; (1992); each incorporated herein in its entirety by reference.
For example, plant expression vectors may include a cloned plant gene under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors may also contain, if desired, a promoter regulatory region one conferring inducible, constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific/selective expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.
Constitutive, tissue-preferred or inducible promoters can be employed.
Examples of constitutive promoters include the cauliflower mosaic virus (CaMV) transcription initiation region, the or promoter derived from T-DNA of Agrobacterium tumefaciens, the actin promoter, the ubiquitin promoter, the histone H2B promoter (Nakayama et al., 1992, FEBS Lett 30:167-170), the Smas promoter, the cinnamyl alcohol dehydrogenase promoter Patent No.
5,683,439), the Nos promoter, the pEmu promoter, the rubisco promoter, the GRP1-8 promoter, and other transcription initiation regions from various plant genes known in the art.
I
Examples of inducible promoters are the Adhl promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, the PPDK promoter which is inducible by light, the In2 promoter which is safener induced, the ERE promoter which is estrogen induced and the Pepcarboxylase promoter which is light induced.
Examples of promoters under developmental control include promoters that initiate transcription preferentially in certain tissues, such as leaves, roots, fruit, seeds, or flowers. An exemplary promoter is the anther specific promoter 5126 Patent Nos. 5,689,049 and 5,689,051). Examples of seed-preferred promoters include, but are not limited to, 27 kD gamma zein promoter and waxy promoter, Boronat, Martinez, Reina, Puigdomenech, P. and Palau, Isolation and sequencing of a 28 kD glutelin-2 gene from maize: Common elements in the 5' flanking regions among zein and glutelin genes; Plant Sci.
47:95-102 (1986) and Reina, Ponte, Guillen, Boronat, A. and Palau, J., Sequence analysis of a genomic clone encoding a Zc2 protein from Zea mays W64 A, Nucleic Adds Res. 18(21):6426 (1990). See the following site relating to the waxy promoter Kloesgen, Giert,A., Schwarz-Sommer, ZS. and Saedler, Molecular analysis of the waxy locus of Zea mays, Mol. Gen. Genet. 203:237- 244 (1986). The disclosures each of these are incorporated herein by reference in their entirety.
Preferably a weak constitutive promoter, such as the Nos promoter, an inducible promoter, such as In2, or a nucellus-preferred or integument-preferred promoter are used to induce apospory. For example the barley or maize Nucl promoter, the maize Cim 1 promoter or the maize LTP2 promoter can be used to preferentially express in the nucellus. See for example US Serial No. 60/097,233 filed August 20, 1998 the disclosure of which is incorporated herein by reference.
Either heterologous or non-heterologous endogenous) promoters can be employed to direct expression of the nucleic acids of the present invention.
These promoters can also be used, for example, in expression cassettes to drive expression of antisense nucleic acids to reduce, increase, or alter concentration and/or composition of the proteins of the present invention in a desired tissue.
If polypeptide expression is desired, it is generally desirable to include a polyadenylation region at the 3'-end of a polynucleotide coding region. The _I -19.
polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA The 3' end sequence to be added can be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or less preferably from any other eukaryotic gene.
An intron sequence can be added to the 5' untranslated region or the coding sequence of the partial coding sequence to increase the amount of the mature message that accumulates. See for example Buchman and Berg, Mol.
Cell Biol. 8:4395-4405 (1988); Callis et Genes Dev. 1:1183-1200 (1987). Use of maize introns Adhl-S intron 1, 2, and 6, the Bronze-1 intron are known in the art. See generally, The Maize Handbook, Chapter 116, Freeling and Walbot, Eds., Springer, New York (1994).
The vector comprising the sequences from a polynucleotide of the present invention will typically comprise a marker gene which confers a selectable phenotype on plant cells. Usually, the selectable marker gene will encode antibiotic or herbicide resistance. Suitable genes include those coding for resistance to the antibiotics spectinomycin and streptomycin the aada gene), the streptomycin phosphotransferase (SPT) gene coding for streptomycin resistance, the neomycin phosphotransferase (NPTII) gene encoding kanamycin or geneticin resistance, the hygromycin phosphotransferase (HPT) gene coding for hygromycin resistance.
Suitable genes coding for resistance to herbicides include those which act to inhibit the action of acetolactate synthase (ALS), in particular the sulfonylurea-type herbicides the acetolactate synthase (ALS) gene containing mutations leading to such resistance in particular the S4 and/or Hra mutations), those which act to inhibit action of glutamine synthase, such as phosphinothricin or basta the bar gene), or other such genes known in the art. The bar gene encodes resistance to the herbicide basta and the ALS gene encodes resistance to the herbicide chlorsulfuron. While useful in conjunction with the above antibiotic and herbicide-resistance selective markers use of the LEC1 gene can increase transformation frequencies when using chemical selection), a prefered use of LEC1 expression takes advantage of this gene conferring a growth advantage to transformed cells without the need for inhibitory compounds to retard non-transformed growth. Thus, LEC1 transformants are recovered based solely on their differential growth advantage.
Typical vectors useful for expression of genes in higher plants are well known in the art and include vectors derived from the tumor-inducing (Ti) plasmid of Agrobacterium tumefadens described by Rogers et al., Meth. In Enzymol.
153:253-277 (1987). Exemplary A. tumefaciens vectors useful herein are plasmids pKYLX6 and pKYLX7 of Schardi et al., Gene, 61:1-11 (1987) and Berger et Proc. Natl. Acad. Sci USA 86:8402-8406 (1989). Another useful vector herein is plasmid p81101.2 that is available from Clontech Laboratories, Inc. (Palo Alto, CA).
A variety of plant viruses that can be employed as vectors are known in the art and include cauliflower mosaic virus (CaMV), geminivirus, brome mosaic virus, and tobacco mosaic virus.
A polynucleotide of the present invention can be expressed in either sense or anti-sense orientation as desired. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, Sheehy et al., Proc. Natl. Acad.
Sci. USA 85:8805-8809 (1988); and Hiatt et al., U.S. Patent No. 4,801,340.
Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method to modulate expression of endogenous genes see, Napoli et al., The Plant Ce/l 2:279-289 (1990) and U.S. Patent No.
5,034,323.
Recent work has shown suppression with the use of double stranded RNA.
Such work is described in Tabara et al., Science 282:5388:430-431 (1998).
Catalytic RNA molecules or ribozymes can also be used to inhibit expression of plant genes. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described in Haseloff et Nature 334:585-591 (1988).
A variety of cross-linking agents, alkylating agents and radical generating species as pendant groups on polynucleotides of the present invention can be I I -21used to bind, label, detect, and/or cleave nucleic acids. For example, Vlassov, V.
et al., Nucleic Acids Res (1986) 14:4065-4076, describe covalent bonding of a single-stranded DNA fragment with alkylating derivatives of nucleotides complementary to target sequences. A report of similar work by the same group is that by Knorre, D. et al., Biochimie (1985) 67:785-789. Iverson and Dervan also showed sequence-specific cleavage of single-stranded DNA mediated by incorporation of a modified nucleotide which was capable of activating cleavage Am. Chem. Soc. (1987) 109:1241-1243). Meyer, R. et al., J. Am. Chem.
Soc. (1989) 111:8517-8519, effect covalent crosslinking to a target nucleotide using an alkylating agent complementary to the single-stranded target nucleotide sequence. A photoactivated crosslinking to single-stranded oligonucleotides mediated by psoralen was disclosed by Lee, B. et al., Biochemistry (1988) 27:3197-3203. Use of crosslinking in triple-helix forming probes was also disclosed by Home, et al., J. Am. Chem. Soc. (1990) 112:2435-2437. Use of N4, N4-ethanocytosine as an alkylating agent to crosslink to single-stranded oligonucleotides has also been described by Webb and Matteucci, J. Am. Chem.
Soc. (1986) 108:2764-2765; Nucleic Acids Res (1986) 14:7661-7674; Feteritz et al., J. Am. Chem. Soc. 113:4000 (1991). Various compounds to bind, detect, label, and/or cleave nucleic acids are known in the art. See, for example, U.S.
Patent Nos. 5,543,507; 5,672,593; 5,484,908; 5,256,648; and, 5,681941.
Proteins There _is herein disclosed an isolated protein comprising a member selected from the group consisting of: a polypeptide comprising at least 25 contiguous amino acids of SEQ ID NO: 2, 8, 10, 12, 14, 16, 18, 20, or 22; a polypeptide which is a plant HAP3-type CCATT-box binding transcriptional activator that regulates gene expression during embryo development and maturation; a polypeptide comprising at least 60% sequence identity to SEQ ID NO: 2, 12, 14,16,20, or 22, or 70 sequence identity to SEQ ID NO: 8, 10, or 18, wherein the sequence identity is based on the entire -22sequence. and is determined by GAP analysis using Gap Weight of 12 and Length Weight of 4; a polypeptide encoded by a nucleic acid of claim 1; a polypeptide encoded by a nucleic acid of SEQ ID NO: 1, 7, 9, 11, 13, 15, 17, 19, or 21; and a polypeptide having the sequence set forth in SEQ ID NO: 2, 8, 12, 14, 16, 18, 20, or 22.
Proteins of the present invention include proteins derived from the native protein by deletion (so-called truncation), addition or substitution of one or more amino acids at one or more sites in the native protein. Such variants may result from, for example, genetic polymorphism or from human manipulation. Methods for such manipulations are generally known in the art.
For example, amino acid sequence variants of the polypeptide can be prepared by mutations in the cloned DNA sequence encoding the native protein of interest. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Walker and Gaastra, eds. (1983) Techniques in Molecular Biology (MacMillan Publishing Company, New York); Kunkel (1985) Proc. Nail. Acad. Sc. USA 82 :488-492; Kunkel et al. (1987) Methods Enzymot. 154:367-382; Sambrook et at. (1989) Molecular Cloning:
A
Laboratory Manual (Cold Spring Harbor, New York); U.S. Patent No. 4,873,192; and the references cited therein; herein incorporated by reference. Guidance as to appropriate amino acid substitutions that do not affect biological activity of the protein of interest may be found in the model of Dayhoff et at. (1978) Atlas of Protein Sequence and Structure (Nati. Biomed. Res. Found., Washington, herein incorporated by reference. Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be preferred.
In constructing variants of the proteins of interest? modifications to the nucleotide sequences encoding the variants will be made such that variants continue to possess the desired activity. Obviously, any mutations made in the DNA encoding the variant protein must not place the sequence out of reading
I
-23frame and preferably will not create complementary regions that could produce secondary mRNA structure. See EP Patent Application Publication No. 75,444.
The isolated proteins of the present invention include a polypeptide comprising at least 23 contiguous amino acids encoded by any one of the nucleic acids of the present invention, or potypeptides which are conservatively modified variants thereof. The proteins of the present invention or variants thereof can comprise any number of contiguous amino acid residues from a polypeptide of the present invention, wherein that number is selected from the group of integers consisting of from 23 to the number of residues in a full-length polypeptide of the present invention. Optionally, this subsequence of contiguous amino acids is at least 25, 30, 35, or 40 amino acids in length, often at least 50, 60, 70, 80, or amino acids in length.
The present invention includes catalytically active polypeptides enzymes). Catalytically active polypeptides will generally have a specific activity of at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% that of the native (non-synthetic), endogenous polypeptide. Further, the substrate specificity is optionally substantially similar to the native (non-synthetic), endogenous polypeptide.
Typically, the K4, will be at least 30%, 40%, or 50%, that of the native (nonsynthetic), endogenous polypeptide; and more preferably at least 60%, or 90%. Methods of assaying and quantifying measures of enzymatic activity and substrate specificity are well known to those of skill in the art.
The present invention includes modifications that can be made to an inventive protein. In particular, it may be desirable to diminish the activity of the LECI gene. Other modifications may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification sequences.
Using the nucleic acids of the present invention, one may express a protein of the present invention in a recombinantly engineered cell such as bacteria,
I
-24yeast, insect, mammalian, or preferably plant cells. The cells produce the protein in a non-natural condition in quantity, composition, location, and/or time), because they have been genetically altered through human intervention to do so.
Typically, an intermediate host cell will be used in the practice of this invention to increase the copy number of the cloning vector. With an increased copy number, the vector containing the gene of interest can be isolated in significant quantities for introduction into the desired plant cells.
Host cells that can be used in the practice of this invention include prokaryotes, including bacterial hosts such as Eschericia coli, Salmonella typhimurium, and Serratia marcescens. Eukaryotic hosts such as yeast or filamentous fungi may also be used in this invention. Since these hosts are also microorganisms, it will be essential to ensure that plant promoters which do not cause expression of the polypeptide in bacteria are used in the vector.
Commonly used prokaryotic control sequences include such commonly used promoters as the beta lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al., Nature 198:1056 (1977)), the tryptophan (trp) promoter system (Goeddel et al., Nucleic Acids Res. 8:4057 (1980)) and the lambda derived P L promoter and N-gene ribosome binding site (Shimatake et Nature 292:128 (1981)). The inclusion of selection markers in DNA vectors transfected in E. coil is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol.
The vector is selected to allow introduction into the appropriate host cell.
Bacterial vectors are typically of plasmid or phage origin. Expression systems for expressing a protein of the present invention are available using Bacillus sp. and Salmonella (Palva, et al., Gene 22:229-235 (1983); Mosbach, et al., Nature 302:543-545 (1983)).
Synthesis of heterologous proteins in yeast is well known. See Sherman, et al., Methods in Yeast Genetics, Cold Spring Harbor Laboratory (1982). Two widely utilized yeast for production of eukaryotic proteins are Saccharomyces cerevisiae and Pichia pastoris. Vectors, strains, and protocols for expression in Saccharomyces and Pichia are known in the art and available from commercial suppliers Invitrogen). Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphoglycerate kinase or alcohol
I
oxidase, and an origin of replication, termination sequences and the like as desired.
A protein of the present invention, once expressed, can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysates. The monitoring of the purification process can be accomplished by using Western blot techniques or radioimmunoassay of other standard immunoassay techniques.
The proteins of the present invention can also be constructed using noncellular synthetic methods. Solid phase synthesis of proteins of less than about 50 amino acids in length may be accomplished by attaching the C-terminal amino acid of the sequence to an insoluble support followed by sequential addition of the remaining amino acids in the sequence. Techniques for solid phase synthesis are described by Barany and Merrifield, Solid-Phase Peptide Synthesis, pp. 3-284 in The Peptides: Analysis, Synthesis, Biology. Vol. 2: Special Methods in Peptide Synthesis, Part Merrifield, et al., J. Am. Chem. Soc. 85:2149-2156 (1963), and Stewart et al., Solid Phase Peptide Synthesis, 2nd ed., Pierce Chem. Co., Rockford, III. (1984). Proteins of greater length may be synthesized by condensation of the amino and carboxy termini of shorter fragments. Methods of forming peptide bonds by activation of a carboxy terminal end by the use of the coupling reagent N,N'-dicycylohexylcarbodiimide)) is known to those of skill.
The proteins of this invention, recombinant or synthetic, may be purified to substantial purity by standard techniques well known in the art, including detergent solubilization, selective precipitation with such substances as ammonium sulfate, column chromatography, immunopurification methods, and others. See, for instance, R. Scopes, Protein Purification: Principles and Practice, Springer-Verlag: New York (1982); Deutscher, Guide to Protein Purification, Academic Press (1990). For example, antibodies may be raised to the proteins as described herein. Purification from E. coli can be achieved following procedures described in U.S. Patent No. 4,511,503. Detection of the expressed protein is achieved by methods known in the art and include, for example, radioimmunoassays, Western blotting techniques or immunoprecipitation.
The present invention further provides a method for modulating increasing or decreasing) the concentration or composition of the polypeptides of
I
-26the present invention in a plant or part thereof. Modulation can be effected by increasing or decreasing the concentration and/or the composition the ratio of the polypeptides of the present invention) in a plant.
The method comprises transforming a plant cell with an expression cassette comprising a polynucleotide of the present invention to obtain a transformed plant cell, growing the transformed plant cell under conditions allowing expression of the polynudceotide in the plant cell in an amount sufficient to modulate concentration andlor composition in the plant cell.
In some embodiments, the content and/or composition of polypeptides of the present invention in a plant may be modulated by altering, in vivo or in vitro, the promoter of a non-isolated gene of the present invention to up- or downregulate gene expression. In some embodiments, the coding regions of native genes of the present invention can be altered via substitution, addition, insertion, or deletion to decrease activity of the encoded enzyme. See, Kmiec, U.S.
Patent 5,565,350; Zarling et al., WO 93/22443. One method of downregulation of the protein involves using PEST sequences that provide a target for degradation of the protein. It has beern observed that high levels of LECI prevent germination. See Lotan et al., Cell 1998 June 26; 93(7):1195-1205. Thus, temporal regulation of LEC1 expression may be desirable in certain species to permit proper germination, vegetative growth, flowering and reproduction.
In some embodiments, an isolated nucleic acid a vector) comprising a promoter sequence is transfected into a plant cell. Subsequently, a plant cell comprising the promoter operably linked to a polynucleotide of the present invention is selected for by means known to those of skill in the art such as, but not limited to, Southern blot, DNA sequencing, or PCR analysis using primers specific to the promoter and to the gene and detecting amplicons produced therefrom. A plant or plant part altered or modified by the foregoing embodiments is grown under plant forming conditions for a time sufficient to modulate the concentration and/or composition of polypeptides of the present invention in the plant Plant forming conditions are well known in the art.
In general, concentration or composition is increased or decreased by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% relative to a native control plant, plant part, or cell lacking the aforementioned expression I I cassette. Modulation in the present invention may occur during and/or subsequent to growth of the plant to the desired stage of development.
Modulating nucleic acid expression temporally and/or in particular tissues can be controlled by employing the appropriate promoter operably linked to a polynucleotide of the present invention in, for example, sense or antisense orientation as discussed in greater detail, supra. Induction of expression of a polynucleotide of the present invention can also be controlled by exogenous administration of an effective amount of inducing compound. Inducible promoters and inducing compounds which activate expression from these promoters are well known in the art. In preferred embodiments, the polypeptides of the present invention are modulated in monocots or dicots, preferably maize, soybeans, sunflower, sorghum, canola, wheat, alfalfa, rice, barley and millet.
Means of detecting the proteins of the present invention are not critical aspects of the present invention. In a preferred embodiment, the proteins are detected and/or quantified using any of a number of well recognized immunological binding assays (see, U.S. Patents 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see also Methods in Cell Biology, Vol. 37: Antibodies in Cell Biology, Asai, Ed., Academic Press, Inc. New York (1993); Basic and Clinical Immunology 7th Edition, Stites Terr, Eds. (1991). Moreover, the immunoassays of the present invention can be performed in any of several configurations, those reviewed in Enzyme Immunoassay, Maggio, Ed., CRC Press, Boca Raton, Florida (1980); Tijan, Practice and Theory of Enzyme Immunoassays, Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers B.V., Amsterdam (1985); Harlow and Lane, supra; Immunoassay: A Practical Guide, Chan, Ed., Academic Press, Orlando, FL (1987); Principles and Practice of Immunoassays, Price and Newman Eds., Stockton Press, NY (1991); and Nonisotopic Immunoassays, Ngo, Ed., Plenum Press, NY (1988).
Typical methods include Western blot (immunoblot) analysis, analytic biochemical methods such as electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, and various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), I I -28immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, and the like.
Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule biotin) is covalently bound to the molecule. The ligand then binds to an anti-ligand streptavidin) molecule which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound. A number of ligands and anti-ligands can be used. Where a ligand has a natural anti-ligand, for example, biotin, thyroxine, and cortisol, it can be used in conjunction with the labeled, naturally occurring anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.
The molecules can also be conjugated directly to signal generating compounds, by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases.
Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, luminol. For a review of various labeling or signal producing systems which may be used, see, U.S. Patent No.
4,391,904, which is incorporated herein by reference.
Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of the target antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.
The proteins of the present invention can be used for identifying compounds that bind to substrates), and/or increase or decrease modulate) the enzymatic activity of, catalytically active polypeptides of the present invention. The method comprises contacting a polypeptide of the present invention with a compound whose ability to bind to or modulate enzyme activity is to be determined. The polypeptide employed will have at least 20%, preferably at least 30% or 40%, more preferably at least 50% or 60%, and most preferably at II I least 70% or 80% of the specific activity of the native, full-length polypeptide of the present invention enzyme). Methods of measuring enzyme kinetics are well known in the art. See, Segel, Biochemical Calculations, 2" d ed., John Wiley and Sons, New York (1976).
Antibodies can be raised to a protein of the present invention, including individual, allelic, strain, or species variants, and fragments thereof, both in their naturally occurring (full-length) forms and in recombinant forms. Additionally, antibodies are raised to these proteins in either their native configurations or in non-native configurations. Anti-idiotypic antibodies can also be generated. Many methods of making antibodies are known to persons of skill.
In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc.
Description of techniques for preparing such monoclonal antibodies are found in, Basic and Clinical Immunology, 4th ed., Stites et Eds., Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane, Supra; Goding, Monoclonal Antibodies: Principles and Practice, 2nd ed., Academic Press, New York, NY (1986); and Kohler and Milstein, Nature 256:495- 497(1975).
Other suitable techniques involve selection of libraries of recombinant antibodies in phage or similar vectors (see, Huse et Science 246:1275- 1281 (1989); and Ward, et al., Nature 341:544-546 (1989); and Vaughan et al., Nature Biotechnology, 14:309-314 (1996)). Alternatively, high avidity human monoclonal antibodies can be obtained from transgenic mice comprising fragments of the unrearranged human heavy and light chain Ig loci minilocus transgenic mice). Fishwild etal., Nature Biotech., 14:845-851 (1996). Also, recombinant immunoglobulins may be produced. See, Cabilly, U.S. Patent No.
4,816,567; and Queen et al., Proc. Natl. Acad. Sci. 86:10029-10033 (1989).
The antibodies of this invention can be used for affinity chromatography in isolating proteins of the present invention, for screening expression libraries for particular expression products such as normal or abnormal protein or for raising anti-idiotypic antibodies which are useful for detecting or diagnosing various pathological conditions related to the presence of the respective antigens.
I
Frequently, the proteins and antibodies of the present invention will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like.
Transfection/Transformation of Cells The method of transformation/transfection is not critical to the instant invention; various methods of transformation or transfection are currently available. As newer methods are available to transform crops or other host cells they may be directly applied. Accordingly, a wide variety of methods have been developed to insert a DNA sequence into the genome of a host cell to obtain the transcription and/or translation of the sequence to effect phenotypic changes in the organism. Thus, any method which provides for efficient transformation/transfection may be employed.
A DNA sequence coding for the desired polynuclectide of the present invention, for example a cDNA or a genomic sequence encoding a full length protein, can be used to construct an expression cassette which can be introduced into the desired plant. Isolated nucleic acid acids of the present invention can be introduced into plants according techniques known in the art. Generally, expression cassettes as described above and suitable for transformation of plant cells are prepared.
Techniques for transforming a wide variety of higher plant species are well known and described in the technical, scientific, and patent literature. See, for example, Weising et Ann. Rev. Genet. 22:421-477 (1988). For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation, PEG poration, particle bombardment, silicon fiber delivery, or microinjection of plant cell protoplasts or embryogenic callus. See, Tomes, et al., Direct DNA Transfer into Intact Plant Cells Via Microprojectile Bombardment. pp.197-213 in Plant Cell, Tissue and Organ Culture, Fundamental Methods. eds. 0. L. Gamborg and G.C. Phillips. Springer- Verlag Berlin Heidelberg New York, 1995. Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional Agrobacterium tumefaciens host vector. The virulence functions of the Agrobacterium tumefaciens host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria.
See, U.S. Patent No. 5,591,616.
The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski et al., Embo J. 3:2717-2722 (1984). Electroporation techniques are described in Fromm et al., Proc. Natl. Acad. Sci. 82:5824 (1985).
Ballistic transformation techniques are described in Klein et al., Nature 327:70-73 (1987).
Agrobacterium tumefaciens-meditated transformation techniques are well described in the scientific literature. See, for example Horsch et al., Science 233:496-498 (1984), and Fraley et al., Proc. Natl. Acad. Sci. 80:4803 (1983). For instance, Agrobacterium transformation of maize is described in WO 98132326.
Agrobacterium transformation of soybean is described in US Pat. No. 5,563,055.
Other methods of transfection or transformation include Agrobacterium rhizogenes-mediated transformation (see, Lichtenstein and Fuller In: Genetic Engineering, Vol. 6, PWJ Rigby, Ed., London, Academic Press, 1987; and Lichtenstein, C. and Draper, In: DNA Cloning, Vol. II, D. M. Glover, Ed., Oxford, IRI Press, 1985), Application PCT/US87/02512 (WO 88/02405 published Apr. 7, 1988) describes the use of A. rhizogenes strain A4 and its Ri plasmid along with A. tumefaciens vectors pARC8 or pARC1 6 liposome-mediated DNA uptake (see, Freeman et al., Plant Cell Physiol. 25:1353, (1984)), the vortexing method (see, Kindle, Proc. Natl. Acad. Sci USA 87:1228, (1990)).
DNA can also be introduced into plants by direct DNA transfer into pollen as described by Zhou et al., Methods in Enzymology, 101:433 (1983); D. Hess, Intern Rev. Cytol., 107:367 (1987); Luo et al., Plane Mol. Biol. Reporter, 6:165 (1988). Expression of polypeptide coding polynucleotides can be obtained by injection of the DNA into reproductive organs of a plant as described by Pena et al., Nature, 325:274 (1987). DNA can also be injected directly into the cells of immature embryos and the rehydration of desiccated embryos as described by
I
Neuhaus et al., Theor. Appl. Genet., 75:30 (1987); and Benbrook et al., in Proceedings Bio Expo 1986, Butterworth, Stoneham, Mass., pp. 27-54(1986). Animal and lower eukaryotic yeast) host cells are competent or rendered competent for transfection by various means. There are several wellknown methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextran, electroporation, biolistics, and micro-injection of the DNA directly into the cells. The transfected cells are cultured by means well known in the art. Kuchler, Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc. (1977).
Altering the culture medium to suppress somatic embryogenesis in nontransformed plant cells andlor tissues to provide for a positive section means of transformed plant cells Using the following methods for controlling somatic embryogenesis, it is possible to alter plant tissue culture media components to suppress somatic embryogenesis in a plant species of interest (often having multiple components that potentially could be adjusted to impart this effect). Such conditions would not impart a negative or toxic in vitro environment for wild-type tissue, but instead would simply not produce a somatic embryogenic growth form. Introducing a transgene such as LEC1 will stimulate somatic embryogenesis and growth in the transformed cells or tissue, providing a clear differential growth screen useful for identifying transformants.
Altering a wide variety of media components can modulate somatic embryogenesis (either stimulating or suppressing embryogenesis depending on the species and particular media component). Examples of media components which, when altered, can stimulate or suppress somatic embryogenesis include; 1) the basal medium itself (macronutrient, micronutrients and vitamins; see T.A.
Thorpe, 1981 for review, "Plant Tissue Culture: Methods and Applications in Agriculture, Academic Press, NY), 2) plant phytohormones such as auxins (indole acetic acid, indole butyric acid, 2,4-dichlorophenoxyacetic acid, naphthaleneacetic acid, picloram, dicamba I I -33and other functional analogues), cytokinins (zeatin, kinetin, benzyl amino purine, 2-isopentyl adenine and functionally-related compounds) abscisic acid, adenine, and gibberellic acid, 3) and other compounds that exert "growth regulator" effects such as coconut water, casein hydrotysate, and proline, and 4) the type and concentration of gelling agent, pH and sucrose concentration.
Changes in the individual components listed above (or in some cases combinations of components) have been demonstrated in the literature to modulate in vitro somatic embryogenesis across a wide range of dicotyledonous and monocotyledonous species. For a compilation of examples, see E.F. George et al. 1987. Plant Tissue Culture Media. Vol. 1: Formulations and Uses.
Exergetics, Ltd., Publ., Edington, England.
Transgenic Plant Regeneration Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype. Such regeneration techniques often rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker that has been introduced together with a polynucleotide of the present invention. For transformation and regeneration of maize see, Gordon-Kamm et al., The Plant Cell, 2:603-618 (1990).
Plants cells transformed with a plant expression vector can be regenerated, from single cells, callus tissue or leaf discs according to standard plant tissue culture techniques. It is well known in the art that various cells, tissues, and organs from almost any plant can be successfully cultured to regenerate an entire plant. Plant regeneration from cultured protoplasts is described in Evans et al., Protoplasts Isolation and Culture, Handbook of Plant Cell Culture, Macmillan Publishing Company, New York, pp. 124-176 (1983); and Binding, Regeneration of Plants, Plant Protoplasts, CRC Press, Boca Raton, pp.
21-73 (1985).
The regeneration of plants containing the foreign gene introduced by Agrobacterium can be achieved as described by Horsch et al., Science, I I -34- 227:1229-1231 (1985) and Fraley et Proc. Natl. Acad. Sci. U.S.A. 80:4803 (1983). This procedure typically produces shoots within two to four weeks and these transformant shoots are then transferred to an appropriate root-inducing medium containing the selective agent and an antibiotic to prevent bacterial growth. Transgenic plants of the present invention may be fertile or sterile.
Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee et al., Ann. Rev. of Plant Phys. 38:467-486 (1987). The regeneration of plants from either single plant protoplasts or various explants is well known in the art. See, for example, Methods for Plant Molecular Biology, A. Weissbach and H.
Weissbach, eds., Academic Press, Inc., San Diego, Calif. (1988). For maize cell culture and regeneration see generally, The Maize Handbook, Freeling and Walbot, Eds., Springer, New York (1994); Corn and Corn Improvement, 3" edition, Sprague and Dudley Eds., American Society of Agronomy, Madison, Wisconsin (1988).
One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.
In vegetatively propagated crops, mature transgenic plants can be propagated by the taking of cuttings, via production of apomictic seed, or by tissue culture techniques to produce multiple identical plants. Selection of desirable transgenics is made and new varieties are obtained and propagated vegetatively for commercial use. In seed propagated crops, mature transgenic plants can be self crossed to produce a homozygous inbred plant. The inbred plant produces seed containing the newly introduced heterologous nucleic acid.
These seeds can be grown to produce plants that would produce the selected phenotype.
Parts obtained from the regenerated plant, such as flowers, seeds, leaves, branches, fruit, and the like are included in the invention, provided that these parts comprise cells comprising the isolated nucleic acid of the present invention.
Progeny and variants, and mutants of the regenerated plants are also included I I within the scope of the invention, provided that these parts comprise the introduced nucleic acid sequences.
Transgenic plants expressing a selectable marker can be screened for transmission of the nucleic acid of the present invention by, for example, standard immunoblot and DNA detection techniques. Transgenic lines are also typically evaluated on levels of expression of the heterologous nucleic acid. Expression at the RNA level can be determined initially to identify and quantitate expressionpositive plants. Standard techniques for RNA analysis can be employed and include PCR amplification assays using oligonucleotide primers designed to amplify only the heterologous RNA templates and solution hybridization assays using heterologous nucleic acid-specific probes. The RNA-positive plants can then analyzed for protein expression by Western immunoblot analysis using the specifically reactive antibodies of the present invention. In addition, in situ hybridization and immunocytochemistry according to standard protocols can be done using heterologous nucleic acid specific polynucleotide probes and antibodies, respectively, to localize sites of expression within transgenic tissue.
Generally, a number of transgenic lines are usually screened for the incorporated nucleic acid to identify and select plants with the most appropriate expression profiles.
A preferred embodiment is a transgenic plant that is homozygous for the added heterologous nucleic acid; a transgenic plant that contains two added nucleic acid sequences, one gene at the same locus on each chromosome of a chromosome pair. A homozygous transgenic plant can be obtained by sexually mating (selfing) a heterozygous transgenic plant that contains a single added heterologous nucleic acid, germinating some of the seed produced and analyzing the resulting plants produced for altered expression of a polynucleotide of the present invention relative to a control plant native, non-transgenic). Backcrossing to a parental plant and out-crossing with a non- transgenic plant are also contemplated. Alternatively, propagation of heterozygous transgenic plants could be accomplished through apomixis.
The present invention provides a method of genotyping a plant comprising a polynucleotide of the present invention. Genotyping provides a means of distinguishing homologs of a chromosome pair and can be used to differentiate segregants in a plant population. Molecular marker methods can be used for phylogenetic studies, characterizing genetic relationships among crop varieties, identifying crosses or somatic hybrids, localizing chromosomal segments affecting monogenic traits, map based cloning, and the study of quantitative inheritance.
See, Plant Molecular Biology: A Laboratory Manual, Chapter 7, Clark, Ed., Springer-Verlag, Berlin (1997). For molecular marker methods, see generally, The DNA Revolution by Andrew H. Paterson 1996 (Chapter 2) in: Genome Mapping in Plants (ed. Andrew H. Paterson) by Academic Press/R. G. Landis Company, Austin, Texas, pp.7-21.
The particular method of genotyping in the present invention may employ any number of molecular marker analytic techniques such as, but not limited to, restriction fragment length polymorphisms (RFLPs). RFLPs are the product of allelic differences between DNA restriction fragments caused by nucleotide sequence variability. Thus, the present invention further provides a means to follow segregation of a gene or nucleic acid of the present invention as well as chromosomal sequences genetically linked to these genes or nucleic acids using such techniques as RFLP analysis.
Plants which can be used in the method of the invention include monocotyledonous and dicotyledonous plants. Preferred plants include maize, wheat, rice, barley, oats, sorghum, millet, rye, soybean, sunflower, alfalfa, canola and cotton.
Seeds derived from plants regenerated from transformed plant cells, plant parts or plant tissues, or progeny derived from the regenerated transformed plants, may be used directly as feed or food, or further processing may occur.
All publications cited in this application are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The present invention will be further described by reference to the following detailed examples. It is understood, however, that there are many extensions, variations, and modifications on the basic theme of the present invention beyond that shown in the examples and description, which are within the spirit and scope of the present invention.
I
-37.
EXAMPLES
Example 1 Library construction used for the maize LEC1 ESTs A. Total RNA Isolation Total RNA was isolated from maize embryo and regenerating callus tissues with TRIzol Reagent (Life Technology Inc. Gaithersburg, MD) using a modification of the guanidine isothiocyanatelacid-phenol procedure described by Chomczynski and Sacchi (Chomczynski, and Sacchi, N. Anal. Biochem. 162, 156 (1987)).
In brief, plant tissue samples were pulverized in liquid nitrogen before the addition of the TRIzol Reagent, and then were further homogenized with a mortar and pestle. Addition of chloroform followed by centrifugation was conducted for separation of an aqueous phase and an organic phase. The total RNA was recovered by precipitation with isopropyl alcohol from the aqueous phase.
B. Poly(A)+ RNA Isolation The selection of poly(A)+ RNA from total RNA was performed using PolyATact system (Promega Corporation. Madison, WI). In brief, biotinylated oligo(dT) primers were used to hybridize to the 3' poly(A) tails on mRNA. The hybrids were captured using streptavidin coupled to paramagnetic particles and a magnetic separation stand. The mRNA was washed at high stringent condition and eluted by RNase-free deionized water.
C. cDNA Library Construction cDNA synthesis was performed and unidirectional cDNA libraries were constructed using the SuperScript Plasmid System (Life Technology Inc.
Gaithersburg, MD). The first stand of cDNA was synthesized by priming an oligo(dT) primer containing a Not I site. The reaction was catalyzed by SuperScript Reverse Transcriptase II at 45°C. The second strand of cDNA was labeled with atpha-3P-dCTP and a portion of the reaction was analyzed by agarose gel electrophoresis to determine cDNA sizes. cDNA molecules smaller than 500 base pairs and unligated adapters were removed by Sephacryl-S400
I
-38chromatography. The selected cDNA molecules were ligated into pSPORT1 vector in between of Not I and Sal i sites.
Example 2 Sequencing and cDNA subtraction procedures used for maize LEC1 ESTrs A. Sequencing Template Preparation Individual colonies were picked and DNA was prepared either by PCR with M13 forward primers and M13 reverse primers, or by plasmid isolation. All the cDNA clones were sequenced using M13 reverse primers.
B. Q-bot Subtraction Procedure cDNA libraries subjected to the subtraction procedure were plated out on 22 x 22 cmn agar plate at density of about 3,000 colonies per plate. The plates were incubated in a 37C incubator for 12-24 hours. Colonies were picked into 384-well plates by a robot colony picker, Q-bot (GENETIX Limited). These plates were incubated overnight at 370C.
Once sufficient colonies were picked, they were pinned onto 22 x 22 cm 2 nylon membranes using Q-bot Each membrane contained 9,216 colonies or 36,864 colonies. These membranes were placed onto agar plate with appropriate antibiotic. The plates were incubated at 37°C for overnight.
After colonies were recovered on the second day, these filters were placed on filter paper prewetted with denaturing solution for four minutes, then were incubated on top of a boiling water bath for additional four minutes. The filters were then placed on filter paper prewetted with neutralizing solution for four minutes. After excess solution was removed by placing the filters on dry filter papers for one minute, the colony side of the filters were place into Proteinase K solution, incubated at 37C for 40-50 minutes. The filters were placed on dry filter papers to dry overnight DNA was then cross-linked to nylon membrane by UV light treatment Colony hybridization was conducted as described by Sambrook, Fritsch, E.F. and Maniatis, (in Molecular Cloning: A laboratory Manual, 2 d Edition).
The following probes were used in colony hybridization: I 1. First strand cDNA from the same tissue from which the library was made to remove the most redundant clones.
2. 48-192 most redundant cDNA clones from the same library based on previous sequencing data.
3. 192 most redundant cDNA clones in the entire corn sequence database.
4. A Sal-A20 oligo nucleotide: TCG ACC CAC GCG TCC GAA AAA AAA AAA AAA AAA AAA, removes clones containing a poly A tail but no cDNA.
cDNA clones derived from rRNA.
The image of the autoradiography was scanned into computer and the signal intensity and cold colony addresses of each colony was analyzed. Re-arraying of cold-colonies from 384 well plates to 96 well plates was conducted using Q-bot Example 3 Identification of Maize LEC1 ESTs from a Computer Homology Search Gene identities were determined by conducting BLAST (Basic Local Alignment Search Tool; Altschul, S. etal., (1993) J. Mol. Biol. 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches under default parameters for similarity to sequences contained in the BLAST nr" database (comprising all nonredundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS- PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm. The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr database using the BLASTX algorithm (Gish, W. and States, D. J. (1993) Nature Genetics 3.266-272) provided by the NCBI. In some cases, the sequencing data from two or more clones containing overlapping segments of DNA were used to construct contiguous DNA sequences.
EXAMPLE 4 Composition of cDNA Libraries Used to Isolate and Sequence Additional cDNA Clones cDNA libraries representing mRNAs from various corn, poppy, soybean and Vemonia tissues were prepared (see Table The characteristics of the libraries are described below.
TABLE 1 cDNA Libraries from Corn, Poppy, Soybean and Vernonia Tissue Corn endosperm 20 days After pollination* Prickly poppy developing seeds Soybean embryo, 6 to 10 days after flowering Soybean embryo, 13 days after flowering Soybean embryogenic suspension 2 weeks after subculture Soybean mature embryo 8 weeks after subculture Soybean embryogenic suspension Vemonia developing seed* *These libraries were normalized essentially as described in U.S. Pat. No.
5,482,845, incorporated herein by reference.
cDNA libraries were prepared in Uni-ZAPTM XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). Conversion of the Uni-ZAP T M XR libraries into plasmid libraries was accomplished according to the protocol provided by Stratagene. Upon conversion, cDNA inserts were contained in the plasmid vector pBluescript. cDNA inserts from randomly picked bacterial colonies containing recombinant pBluescript plasmids were amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences or plasmid DNA was prepared from cultured bacterial cells. Amplified insert DNAs or plasmid DNAs were sequenced in dyeprimer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams, M. D. et al., (1991) Science 252:1651).
II
The resulting ESTs were analyzed using a Perkin Elmer Model 377 fluorescent sequencer.
EXAMPLE S Identification of cDNA Clones obtained from tissue described in Table 1 ESTs encoding plant transcription factors were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul, S. et (1993) J. Mol.
Biol. 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches for similarity to sequences contained in the BLAST "nr" database (comprising all nonredundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS- PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example i were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI).
The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish, W. and States, D. J. (1993) Nature Genetics 3:266-272 and Altschul, Stephen et al. (1997) Nucleic Acids Res.
25:3389-3402) provided by the NCBI.
Example 6 Identification of protein motifs diagnostic for LECI genes.
To determine the structural requirements for a LEC1 gene, HAP3 homologs were identified in our EST database and aligned. By analyzing sequence homology amongst the plant HAP3 family of transcriptional activators these sequences were observed to fall into a least two distinctive groups. All of the HAP3 sequences derived from seed or embryo specific libraries form a distinctive LEC1 group that suggests a common evolutionary origin (confirmed by phylodentrograms). For example within the "B domain" of all plant LECI sequences examined, a highly conserved CCAAT-box binding motif has been -42found to contain the non-variable residues methionine, proline, isoleucine, alanine, asparagine, valine, and isoleucine (MPIANVI). LEC1 genes are highly divergent outside of the region spanning the DNA binding and subunit interaction motifs. The low levels of homology between these genes make it difficult to identify these based solely on a hybridization strategy. Using sequences from maize, soybean, wheat, prickly poppy, Vernonia, and Arabidopsis a motif diagnostic for LEC1 genes was identified, the specific amino acid substitutions for these species was clarified (Figure 1) and the positions at which amino acid substitutions occur within the LEC1 group was determined (SEQ ID NO: 23).
Using Blast, the motif in SEQ ID NO: 23 was used to correctly distinguish LECI's from other closely related plant HAP3 transcriptional activators.
Example 7 Transformation and Regeneration of Maize Callus Immature maize embryos from greenhouse or field grown High type II donor plants were bombarded with a plasmid containing a polynucleotide of the invention (LEC1). The LEC1 polynucleotide was operably linked to a constitutive promoter such as nos, or an inducible promoter, such as ln2, plus a plasmid containing the selectable marker gene PAT (Wohlleben et al. (1988) Gene 70:25- 37) that confers resistance to the herbicide Bialaphos fused to the Green Fluorescence protein. Transformation was performed as follows.
The ears were surface sterilized in 50% Chlorox bleach plus 0.5% Micro detergent for 20 minutes, and rinsed two times with sterile water. The immature.
embryos were excised and placed embryo axis side down (scutellum side up), embryos per plate. These were cultured on 560 L medium 4 days prior to bombardment in the dark. Medium 560 L is an N6-based medium containing Eriksson's vitamins, thiamine, sucrose, 2,4-D, and silver nitrate. The day of bombardment, the embryos were transferred to 560 Y medium for 4 hours and were arranged within the 2.5-cm target zone. Medium 560Y is a high osmoticum medium (560L with high sucrose concentration).
A plasmid vector comprising a polynucleotide of the invention operably linked to the selected promoter was constructed. This plasmid DNA plus plasmid I -43- DNA containing a PAT selectable marker was precipitated onto 1.1 mun (average diameter) tungsten pellets using a CaC12 precipitation procedure as follows: 100 pI prepared tungsten particles (0.6 mg) in water, 20 pi (2 pg) DNA in TrisEDTA buffer (1 tg total), 100 gil 2.5 M CaCl 2 40 pl 0.1 M spermidine.
Each reagent was added sequentially to the tungsten particle suspension.
The final mixture was sonicated briefly. After the precipitation period, the tubes were centrifuged briefly, liquid removed, washed with 500 ml 100% ethanol, and centrifuged again for 30 seconds. Again the liquid was removed, and 60 Al 100% ethanol was added to the final tungsten particle pellet. For particle gun bombardment, the tungsten/DNA particles were briefly sonicated and 5 pi spotted onto the center of each macrocarrier and allowed to dry about 2 minutes before bombardment.
The sample plates were bombarded at a distance of 8 cm from the stopping screen to the tissue, using a Dupont biolistics helium particle gun. All samples received a single shot at 650 PSI, with a total of ten aliquots taken from each tube of prepared particles/DNA.
Four to 12 hours post bombardment, the embryos were moved to 560P (a low osmoticum callus initiation medium similar to 560L but with lower silver nitrate), for 3-7 days, then transferred to 560R selection medium, an N6 based medium similar to 560P containing 3 mg/liter Bialaphos, and subcultured every 2 weeks. Multicellular GFP cell clusters became visible after two weeks and their numbers were periodically recorded. After approximately 10 weeks of selection, selection-resistant GFP positive callus clones were sampled for PCR and activity of the polynucleotide of interest. Positive lines were transferred to 288J medium, an MS-based medium with lower sucrose and hormone levels, to initiate plant regeneration. Following somatic embryo maturation (2-4 weeks), well-developed somatic embryos were transferred to medium for germination and transferred to the lighted culture room. Approximately 7-10 days later, developing plantlets were transferred to medium in tubes for 7-10 days until plantlets were well established. Plants were then transferred to inserts in flats (equivalent to pot) containing potting soil and grown for I week in a growth chamber, subsequently grown an additional 1-2 weeks in the greenhouse, then transferred
I
to Classic" 600 pots (1.6 gallon) and grown to maturity. Plants are monitored for expression of the polynucleotide of interest Example 8 Ectopic Expression of Maize LEC1 to Induce Somatic Embryogenesis Using the genotype High type II as an example, embryos were isolated and cultured on 560L medium for 3-5 days. Four to twelve hours before bombardment these embryos were transferred to high osmotic 560Y medium. Expression cassettes containing the LEC1 cDNA were then co-introduced into the scutella of these embryos along with an expression cassette containing the Pat gene fused to the Green Fluorescent protein using methods described in Example 7.
Embryos from a single ear were divided evenly between treatments. Four to 12 hours following bombardment embryos were then transferred back to a low osmoticum callus initiation medium (560P) and incubated in the dark at 26 0
C.
After 3-7 days of culture these embryos were moved to 560R selection medium.
Cultures were then transferred every two weeks until transformed colonies appear. Cultures were also examined microscopically for GFP expression. LEC1 expression was expected to stimulate adventive embryo formation. This was apparent when the cultures were compared to controls (transformed without the LEC1 cDNA or non-induced).
A. Ectopic expression of the maize LEC1 polynucleotide in tobacco. is sufficient to induce somatic embryogenesis in tobacco leaves A maize LEC1 polynucleotide was placed into an agrobacterium expression cassette driven by the maize safener-induced In2 promoter (this promoter is leaky and expresses at low levels without induction). Also between the left and right T-DNA borders was the bar gene driven by 35S promoter and the Green Fluorescence Protein driven by the ubiquitin promoter. A similar construct was made without the LEC1 polynucleotide to be used as a control.
Tobacco leaf discs from variety SR1 were co-cultured with Agrobacterium as described by Horsch et al. (1985, Science 227:1229-1231) except selecting with bialaphos ratherthan kanamycin. Transformants were selected on medium
I
containing 3mg/ bialaphos. Of the numerous transformed shoot obtained, ectopic embryos were visible on the leaves of a single LEC1 transformant. None were visible on control plants. Although the frequency was low, ectopic somatic embryo formation was also reported to be a rare event in Arabidopsis LEC1 transformants (Lotan et al. 1998).
B. Transformation frequency was improved by LECI introduced using particle-mediated DNA delivery.
A series of expression cassettes were made to evaluate the effects of LEC1 expression on maize transformation. The maize LEC1 polynucleotide was placed under the control of the In2 promoter (weakly induced with the auxin levels used under normal culture conditions and strongly-induced with safener), the barley NUC1 promoter (expressed strongly in the nucellus), the Ubiquitin promoter (strongly expressed constitutively), and the nos promoter (weakly expressed constitutively). A frame-shift version of the In2:LEC1 cassette was made along with an In2:ZM-NF-YB (designated as ln2:HAP3 henceforth) construct (The maize ZM NF-YB is non-LEC1 type of HAP3 transcriptional activator (Li et al Nucleic Acids Res. 20:1087-1091) for use as negative controls.
All of these constructs were co-bombarded with the Pat-GFP fusion construct (designated as PAT-GFP) into high type II embryos as described in Example 7.
Also, as in Example 7, immature embryos were harvested from separate ears, and the embryos from each ear were divided equally between treatments to account for ear-to-ear variability (for example, in an experiment comparing a control plasmid with this same plasmid LEC1, one-half the total embryos from each ear would be used for each treatment. In some cases the control treatment contained the Pat-GFP construct co-bombarded with GUS. Transformation frequency was determined by counting the numbers of embryos with large multicellular GFPpositive cells clusters using a GFP microscope, and representing these as a percentage of the original number of embryos bombarded. No distinction was made between embryos with single or multiple events. In all cases, the functional LEC1 expression cassettes increased transformation frequencies over the control treatment (the LECI expression cassette also increased the incidence of multiple, i.e. 2-3, multicellular transgenic clones growing from the same immature embryo,
I
-46but as stated above we only scored these as a single event, and are providing a conservative representation of LEC1's ability to improve transformation). For example, transformation frequencies in control treatments for three consecutive experiments were 5.1, 7.4 and In balanced side-by-side comparisons for the same three experiments, transformation frequencies with the LEC1 polynucleotide (In2::LEC1::pinll) were 28.8, 25.7 and 12.4%, respectively. In addition to increasing the absolute number of transformants recovered from a given amount of target tissue, LEC1 transformants appeared earlier than the control transformants (suggesting that the LEC1 polynucleotide also stimulated growth rates).
As a more stringent control, an expression vector was constructed in which a LEC1 gene, frame-shifted immediately after the start codon, was placed behind the In2 promoter. In this experiment using embryos from 3 separate ears, the transformation frequencies in the control (frame-shifted LEC1) treatments were 2.7, 6.0 and while the transformation frequencies for the LEC1 treatments were 62.7, 26 and 42.7%. This demonstrated clearly that expression of the inframe LEC1 polynucleotide was associated with dramatic increases in transformation efficiency.
Increasing the promoter strength (driving LEC1 expression) increased transformation frequencies. For example, an experiment was performed to compare the In2, nos and UBI promoters. Based on our experience with these two promoters driving other genes, the ln2 promoter (in the absence of an inducer other than auxin from the medium) would drive expression at very low levels. The nos promoter has been shown to drive moderately-low levels of transgene expression (approximately 10- to 30-fold lower than the maize ubiquitin promoter, but still stronger than ln2 under the culture conditions used in this experiment).
Two control treatments were used in this experiment; the frame-shifted LEC1 driven by the In2 promoter, or a maize In2:HAP3 polynucleotide (a "non-LEC1 type" representative of the transcriptional factor family to which LEC1 belongs).
Both control treatments resulted in low transformation frequencies. After 3 weeks, the transformation frequency for the In2:frame-shift-LEC1 (FS) treatment was while for the In2:HAP3 treatment it was The In2:LEC1, nos:LEC1 and UBI:LEC1 treatments resulted in 14%, 28% and 30% transformation frequencies,
I
-47respectively. Within these treatments there was also an increase in the overall frequency of large, rapidly growing calli. For the control treatments, the frequencies of large, vigorous GFP+ calli (relative to the starting number of embryos) was low (1.6 and 0% for the frame-shift or In2:HAP3, respectively). For the In2, nos and UBI treatments the overall frequencies of large vigorous calliwas 4, 13.3 and 20%, respectively. This is consistent with the interpretation that increased LEC1 expression resulted in more rapid in vitro growth of transgenic tissue. As is typical for transformation experiments scored in this fashion, between 3-6 weeks the number of recovered transformants continues to rise.
After 5 weeks (post-bombardment), the frequency of healthy, growing transformants was 4.8 and 7.3% for the FS and HAP3 controls, while for the ln2, nos and UBI-driven LECI treatments the frequencies were 22, 29.3 and 35.3%.
C. Transformation frequency was improved by LECl introduced using agrobacterium.
The Agrobacterium strains containing the superbinary plasmids described in Example 8A were used to transformed High type II embryos. Briefly, colonies containing the engineered Agrobacterium were grown to log phase in minimal A medium. Log phase cells were collected by centrifugation and resuspended in 561Q medium (N6 salts, Eriksson's vitamins, 1.5mg/I 2,4-D, 68.5g/l sucrose, 36g/1 glucose, plus 20mg/i acetosyringone). Immature embryos, 1.5-2mm in length, were excised and immersed in this solution at a concentration of 5 X 10 8 bacterial cells/ml. Embryos were vortexed in this medium and allowed to sit for minutes. The embryos were then removed and placed on 562P medium (560P medium with 100mM acetosyringone and incubated at 20°C for 3 days. Embryos were moved again to 563N medium (an agar solidified medium similar to 560P with 100mg/I carbenicillin, 0.5g/I MES and reduced 2,4-D) and cultured at 28'C for 3 days. Embryos were then moved to 5630 medium (563N medium with 3mg/ bialaphos) and transferred thereafter every 14 days to fresh 5630 medium.
Bialaphos resistant GFP+ colonies were counted using a GFP microscope and transformation frequencies were determined as described in example 8B.
Similar to particle gun experiments, transformation frequencies were greatly increased in the LECl treatment For example, transformation frequencies for the I I control treatment across embryos taken from 7 separate ears were 7.1, 40.9, 11.1, 7.4, 11.5, 12, 30.8, and 16.6%. The side-by-side comparison for the LEC treatment (in the same order of ears as above) showed that transformation frequencies were 13.5, 47, 55.8, 37.1, 40.6, 30, 57.1 and 40.8%. Averaged across all 7 ears, the average transformation frequency for the control was 16.6% while that of the LEC1 treatment was 40.8%. This represents a substantial increase for an already high baseline produced by Agrobacterium-mediated transformation. Comparing across ears, it was observed that the beneficial effects on transformation frequency were the greatest when the control frequencies were low.
D. Transformants were recovered using LECI expression under reduced auxin levels or in the absence of auxins in the medium, and in the absence of herbicide or antibiotic selection.
To determine if LEC1 could be used in a positive selection scheme, particle gun transformation experiments were initiated as described in Example 4 and transformants were selected on medium with normal auxin levels, or on medium with reduced or no auxin, or visually (using GFP) on medium without bialaphos. Transformation frequencies were based on the numbers of embryos with one or more multicellular GFP positive cell clusters. In the first experiment to test this concept, there were two treatment variables. The first was that immature embryos were bombarded with the control plasmid (UBI:PAT-GFP) or with UBI:PAT-GFP+ln2:LEC1. The second variable was that the bombarded embryos were divided onto either normal bialaphos-containing selection medium (with normal auxin levels of 2 mg/I or medium with no bialaphos and reduced 2,4-D levels (0.5 mg/I). As expected from previous results, on bialaphos selection the LEC1 treatment resulted in a higher transformation frequency than the control (5.7 versus It was also anticipated that the low auxin medium (0.5 mg/I 2,4-D) would result in reduced growth rates. Consistent with this, for the control plasmid treatment (UBI:PAT~GFP), recovery of GFP-expressing (fluorescent) colonies was reduced relative to highly-effective bialaphos-selection treatment, dropping down to In contrast, it appeared that LEC1 expression, through its stimulation of embryogenesis, may have compensated for the low auxin I I -49environment, providing a growth advantage to the transgenic colonies, and maintaining the efficiency of transformant recovery at 4.0% (still in the same range as the LEC/bialaphos-selected treatment). It's clear from this result that the inclusion of LEC1 improved colony growth on reduced auxin relative to the control.
On medium completely devoid of auxin, colonies were only observed in the LEC1 treatment. In this experiment, immature embryos were bombarded with either the control plasmid (UBI:PAT~GFP) or with UBI:PAT~GFP+ln2:LEC1, and then plated either onto 3.0 mg/l bialaphos, 2.0 mg1 2,4-D medium or onto nobialaphos, no 2,4-D medium (in this latter treatment, wild-type maize callus will not exhibit embryogenic growth). Again, as expected, the LEC1 polynucleotide increased transformation to 22.7% over the control plasmid value of 8% on normal auxin-containing, bialaphos selection medium. Also, as expected, no transformants were recovered with the control plasmid on medium devoid of exogenous auxin. Surprisingly, in the LEC1 treated embryos transformants were recovered at a 4% frequency (this was still higher than the control plasmid on bialaphos selection).
Even on auxin-containing medium, the LEC1 polynucleotide in combination with GFP+ expression can be used to recover transformants without chemical selection. For example, under these conditions the recovery of transformants was relatively efficient (16% compared to 18% for bialaphos selection), but this required more diligence than the low- or no-auxin treatments above to separate the GFP-expressing colonies from the growing callus population.
E. LECI improves the embryogenic phenotype and regeneration capacity of inbreds.
Immature embryos from the inbred PHP38 were isolated, cultured and transformed as described in example 4 with the following changes. Embryos were initially cultured on 601H medium (a MS based medium with 0.1 mg/1 zeatin, 2mg/I 2,4-D, MS and SH vitamins, proline, silver nitrate, extra potassium nitrate, casein hydrolysate, gelrite, 10g/l glucose and 20g/l sucrose). Prior to bombardment embryos were moved to a high osmoticum medium (modified Duncan's with 2mg/1 2,4-D and 12% sucrose). Post bombardment, embryos were moved to 601H medium with 3mg/l bialaphos for two weeks. Embryos were then moved to 601H medium without proline and casein hydrolysate with 3mg/I bialaphos and transferred every two weeks. Transformation frequency was determined by counting the numbers of bialaphos resistant GFP-positive colonies. Colonies were also scored on whether they had an embryogenic (regenerable) or nonembryogenic phenotype. In PHP38, the LEC1 polynucleotide increased transformation frequency and improved the regenerative potential of the callus.
For example, a balanced experiment (the embryos from each harvested ear were divided equally between treatments) was conducted in which PHP38 immature embryos were bombarded with the control plasmid (UBI::PAT~GFP::pinll) in one treatment, with the UBI::PAT~GFP::pinll plasmid In2::LEC1, or with the UBI::PAT-GFP::pinll plasmid nucl::LEC1 (a maize nucellus-specific promoter driving LEC1 expression). The frequency of GFP+ calli growing on bialaphoscontaining media (relative to the starting number of embryos) was determined 6 weeks after bombardment. For the control treatment, the transformation frequency was while for the In2:LEC1 and nucl::LEC1 treatments the transformation frequencies were 3.2 and 2.0% respectively. In addition, the presence of the LEC1 polynucleotide appeared to greatly improve the regeneration capacity of the recovered transformants. None of the control transformants (UBI::PAT-GFP::pinll alone) had an embryogenic, regenerable phenotype, while the transformants recovered from the In2:LEC1 and nucl::LEC1 treatments all exhibited a more vigorous, embryogenic growth pattern. This has been bor out in the ability to recover plants. Callus from the In2:LEC1 and nucl::LEC1 treatments has produced many healthy plants.
Example 9 Transient Expression of the LECI polynucleotide Product to Induce Somatic Embryogenesis It may be desirable to "kick start" somatic embryogenesis by transiently expressing the LEC-1 polynucleotide product. This can be done by delivering LEC1 5'capped polyadenylated RNA, expression cassettes containing LEC-1 DNA, or LEC-1 protein. All of these molecules can be delivered using a biolistics
I
-51 particle gun. For example 5'capped polyadenylated LEC1 RNA can easily be made in vitro using Ambion's mMessage mMachine kit. Following the procedure outline above RNA is co-delivered along with DNA containing an agronomically useful expression cassette. The cells receiving the RNA will immediately form somatic embryos and.a large portion of these will have integrated-the-agronemic gene. Plants regenerated from these embryos can then be screened for the presence of the agronomic gene, Example Use of the maize LEC1 to induce apomixis Maize expression cassettes directing LEC1 expression to the inner integument or nucellus can easily be constructed. An expression cassette directing expression of the LEC1 polynucleotide to the nuceilus was made using the barley Nucl promoter. Embryos were co-bombarded with the selectable marker PAT fused to the GFP gene along with the nucellus specific LEC1 expression cassette described above. Both inbred (PHP38) and GS3 transformants were obtained and regenerated as described in examples 4 and Transformation frequencies were also increased over the control using the nucl:LEC1 polynucleotide (see Example 8 above).
It is anticipated that the regenerated plants will then be capable of producing de novo embryos from LEC1 expressing nucellar cells. This is complemented by pollinating the ears to promote normal central cell fertilization and endosperm development In another variation of this scheme, nucl:LEC transformations could be done using a FIE-null genetic background which would promote both de novo embryo development and endosperm development without fertilization (see Ohad et al. 1999 The Plant Cell 11:407-415; also WO 01/16325). Upon microscopic examination of the developing embryos it will be apparent that apomixis has occurred by the presence of embryos budding off the nucellus. In yet another variation of this scheme the LECi polynucleotide could be delivered as described above into a homozygous zygotic-embryo-lethal genotype. Only the adventive embryos produced from somatic nucellus tissue would develop in the seed.
I
-52- EXAMPLE 11 Expression of Chimeric Genes in Microbial Cells The cDNAs encoding the instant transcription factors can be inserted into the T7 E coli expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) Gene 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.
Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1 NuSieve GTG TM low melting agarose gel (FMC). Buffer and agarose contain 10 pg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase
T
(Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 pL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 pg/mL ampicillin. Transformants containing the polynucleotide encoding the
I
-53transcription factor are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.
For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the 17 promoter can be transformed into E. coil strain BL21 (DE3) (Studier et al. (1986) J. Mol. Biol. 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25'C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-p-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 hours at 25C. Cells are then harvested by centrifugation and resuspended in 50 pL of 50 mM Tris-HCI at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supematant determined. One pg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.
EXAMPLE 12 Evaluating Compounds for Their Ability to Inhibit the Activity of Plant Transcription Factors The transcription factors described herein may be produced using any number of methods known to those skilled in the art. Such methods include, but are not limited to, expression in bacteria as described in Example 6, or expression in eukaryotic cell culture, in planta, and using viral expression systems in suitably infected organisms or cell lines. The instant transcription factors may be expressed either as mature forms of the proteins as observed in vivo or as fusion proteins by covalent attachment to a variety of enzymes, proteins or affinity tags.
Common fusion protein partners include glutathione S-transferase thioredoxin maltose binding protein, and C- and/or N-terminal hexahistidine polypeptide The fusion proteins may be engineered with a protease recognition site at the fusion point so that fusion partners can be separated by protease digestion to yield intact mature enzyme. Examples of such .54.
proteases include thrombin, enterokinase and factor Xa. However, any protease can be used which specifically cleaves the peptide connecting the fusion protein and the enzyme.
Purification of the instant transcription factors, if desired, may utilize any number of separation technologies familiar to those skilled in the art of protein purification. Examples of such methods include, but are not limited to, homogenization, filtration, centrifugation, heat denaturation, ammonium sulfate precipitation, desalting, pH precipitation, ion exchange chromatography, hydrophobic interaction chromatography and affinity chromatography, wherein the affinity ligand represents a substrate, substrate analog or inhibitor. When the transcription factors are expressed as fusion proteins, the purification protocol may include the use of an affinity resin which is specific for the fusion protein tag attached to the expressed enzyme or an affinity resin containing ligands which are specific for the enzyme. For example, a transcription factor may be expressed as a fusion protein coupled to the C-terminus of thioredoxin. In addition, a (His) 6 peptide may be engineered into the N-terminus of the fused thioredoxin moiety to afford additional opportunities for affinity purification. Other suitable affinity resins could be synthesized by linking the appropriate ligands to any suitable resin such as Sepharose-4B. In an alternate embodiment, a thioredoxin fusion protein may be eluted using dithiothreitol; however, elution may be accomplished using other reagents which interact to displace the thioredoxin from the resin. These reagents include -mercaptoethanol or other reduced thiol.
The eluted fusion protein may be subjected to further purification by traditional means as stated above, if desired. Proteolytic cleavage of the thioredoxin fusion protein and the enzyme may be accomplished after the fusion protein is purified or while the protein is still bound to the ThioBond T M affinity resin or other resin.
Crude, partially purified or purified enzyme, either alone or as a fusion protein, may be utilized in assays for the evaluation of compounds for their ability to inhibit enzymatic activition of the transcription factors disclosed herein. Assays may be conducted under well-known experimental conditions that permit optimal enzymatic activity.
I Example 13 LEC1 expression resulted in increased growth rates, which could be used as a screening criterion for positive selection of transformants.
Using two promoters of increasing strength to drive LEC1 expression in maize; it appeared that LEC1 stimulated callus growth over control treatments and the stronger promoter driving LEC1 resulted in faster growth than with the low-level promoter. For example, an experiment was performed to compare the In2 and nos promoters. As noted above, based on our experience with these two promoters driving other genes, the In2 promoter (in the absence of an inducer other than auxin from the medium) would drive expression at very low levels. The nos promoter has been shown to drive moderately-low levels of transgene expression (approximately 10- to 30-fold lower than the maize ubiquitin promoter, but still stronger than ln2 under the culture conditions used in this experiment).
One control treatment was used in this experiment, the UBI:PAT~GFPmo:pinll construct by itself (with no LEC1). Hi-ll immature embryos were bombarded as previously described, and transgenic, growing events were scored at 3 and 6 weeks. The control treatment resulted in a transformation frequency of 0.8%.
The In2:LEC1 and nos:LEC1 treatments resulted in transformation frequencies of 26.5 and 40.7%, respectively.
Within these treatments there was also an increase in the overall frequency of large, rapidly growing calli, relative to the control treatment. For this data, the fresh weight of transformed calli were recorded 2 months after bombardment.
Assuming that all the transgenic events started as single transformed cells within a few days after bombardment, these weights represent the relative growth rate of these transformants during this period (all tissue was sub-cultured and weighed for each transformant; mean weights and standard deviations were calculated for each treatment). For the control treatment, the mean transformant weight after two months was 37 15 mg For the In2:LEC1 and nos:LEC1 treatments, the mean transformant weights were 126 106 and 441 430 mg, respectively. If the control treatment was set at a relative growth value of 1.0, this means that transformants in the In2:LEC1 and nos:LEC1 treatments grew 3.4 and
I
-56- 12-fold faster than the control. From this data, it appears that increasing LEC1 expression resulted in a concomitant increase in callus growth rate.
Example 14 The use of LEC1 polynucleotide as a positive seletionsystenfo-rwheat transformation and for improving the regeneration capacity of wheat tissues Method Plant Material Seeds of wheat Hybrinova lines NH535 and BO 014 were sown into soil in plug trays for vemalisation at 6°C for eight weeks. Vernalized seedlings were transferred in 8" pots and grown in a controlled environment room. The growth conditions used were; 1) soil composition: 75% L&P fine-grade peat, 12% screened sterilized loam, 10% 6 mm screened, lime-free grit, 3% medium grade vermiculite, 3.5 kg Osmocote per m 3 soil (slow-release fertiliser, 15-11-13 NPK plus micronutrients), 0.5 kg PG mix per m 3 (14-16-18 NPK granular fertiliser plus micronutrients, 2) 16 h photoperiod (400W sodium lamps providing irradiance of ca. 750 pE s 1 m 2 18 to 20°C day and 14 to 16°C night temperature, 50 to relative air humidity and 3) pest control: sulphur spray every 4 to 6 weeks and biological control of thrips using Amblyseius caliginosus (Novartis BCM Ltd, UK).
Isolation of Explants and Culture Initiation Two sources of primary explants were used; scutellar and inflorescence tissues. For scutella, early-medium milk stage grains containing immature translucent embryos were harvested and surface-sterilized in 70% ethanol for min and 0.5% hypochlorite solution for 15-30 min. For inflorescences, tillers containing 0.5-1.0 cm inflorescences were harvested by cutting below the inflorescence-bearing node (the second node of a tiller). The tillers were trimmed to approximately 8-10 cm length and surface-sterilized as above with the upper end sealed with Nescofilm (Bando Chemical Ind. Ltd, Japan).
Under aseptic conditions, embryos of approximately 0.5-1.0 mm length were isolated and the embryo axis removed. Inflorescences were dissected from thetilledrsand-cut-into-approximately 1-mm-pieces: -Thirty scutella-or 1-mm-
I
-57inflorescence explants were placed in the center (18 mm target circle) of a 90 mm Petri dish containing MD0.5 or L7D2 culture medium. Embryos were placed with the embryo-axis side in contact with the medium exposing the scutellum to bombardment whereas inflorescence pieces were placed randomly. Cultures were incubated at 25±°C in darkness for approximately 24 h before bombardment.
After bombardment, explants from each bombarded plate were spread across three plates for callus induction.
Culture Media The standard callus induction medium for scutellar tissues consisted of solidified Agargel, Sigma A3301) modified MS medium supplemented with 9% sucrose, 10 mg 1 AgNO 3 and 0.5 mg I' 2,4-D (Rasco- Gaunt et al., 1999). Inflorescence tissues were cultured on L7D2 which consisted of solidified Agargel) L3 medium supplemented with 9% maltose and 2 mg 1' 1 2,4-D (Rasco-Gaunt and Barcelo, 1999). The basal shoot induction medium, RZ contained L salts, vitamins and inositol, 3% w/v maltose, 0.1 mg P 2,4-D and mg P zeatin (Rasco-Gaunt and Barcelo, 1999). Regenerated plantlets were maintained in RO medium with the same composition as RZ, but without 2,4-D and zeatin.
DNA Precipitation Procedure and Particle Bombardment Submicron gold particles (0.6 pm Micron Gold, Bio-Rad) were coated with a plasmid containing the maize In-2:LEC1 construct following the protocol modified from the original Bio-Rad procedure (Barcelo and Lazzeri, 1995). The standard precipitation mixture consisted of 1 mg of gold particles in 50 pl SDW, pl of 2.5 M calcium chloride, 20 pl of 100 mM spermidine free base and 5 pl DNA (concentration 1 pg pfr). After combining the components, the mixture was vortexed and the supematant discarded. The particles were then washed with 150 pl absolute ethanol and finally resuspended in 85 pl absolute ethanol. The DNA/gold ethanol solution was kept on ice to minimise ethanol evaporation. For each bombardment, 5 pl of DNA/gold ethanol solution (ca. 60 pg gold) was loaded onto the macrocarrier.
1
I
-SB-
Particle bombardments were carried out using DuPont PDS 1000/He gun with a target distance of 5.5 cm from the stopping plate at 650 psi acceleration pressure and 28 in. Hg chamber vacuum pressure.
Regeneration of Transformants For callus induction, bombarded explants were distributed over the surface of the medium in the original dish and two other dishes and cultured at 25+1°C in darkness for three weeks. Development of somatic embryos from each callus were periodically recorded. For shoot induction, calluses were transferred to RZ medium and cultured under 12 h light (250 pE s" m- 2 from cool white fluorescent tubes) at 25+1 0 C for three weeks for two rounds. All plants regenerating from the same callus were noted. Plants growing more vigorously than the control cultures were potted in soil after 6-9 weeks in RO medium. The plantlets were acclimatized in a propagator for 1-2 weeks. Thereafter, the plants were grown to maturity under growth conditions described above.
DNA Isolation from Callus and Leaf Tissues Genomic DNA was extracted from calluses or leaves using a modification of the CTAB (cetyltriethylammonium bromide, Sigma H5882) method described by Stacey and Isaac (1994). Approximately 100-200 mg of frozen tissues was ground into powder in liquid nitrogen and homogenised in 1 ml of CTAB extraction buffer CTAB, 0.02 M EDTA, 0.1 M Tris-CI pH 8, 1.4 M NaCI, 25 mM DTT) for min at 65°C. Homogenised samples were allowed to cool at room temperature for 15 min before a single protein extraction with approximately 1 ml 24:1 v/v chloroform:octanol was done. Samples were centrifuged for 7 min at 13,000 rpm and the upper layer of supernatant collected using wide-mouthed pipette tips.
DNA was precipitated from the supernatant by incubation in 95% ethanol on ice for I h. DNA threads were spooled onto a glass hook, washed in 75% ethanol containing 0.2 M sodium acetate for 10 min, air-dried for 5 min and resuspended in TE buffer. Five pl RNAse A was added to the samples and incubated at 37°C for 1 h.
II I -59- For quantification of genomic DNA, gel electrophoresis was performed using an 0.8% agarose gel in Ix TBE buffer. One microlitre of the samples were fractionated alongside 200, 400, 600 and 800 ng pl 1 A uncut DNA markers.
Polymerase chain reaction (PCR) analysis The presence of the maize LEC1 polynucleotide was analyzed by PCR using 100-200 ng template DNA in a 30 ml PCR reaction mixture containing 1X concentration enzyme buffer (10 mM Tris-HCI pH 8.8, 1.5 mM magnesium chloride, 50 mM potassium chloride, 0.1% Triton X-100), 200 pM dNTPs, 0.3 pM primers and 0.022 U TaqDNA polymerase (Boehringer Mannheim).
Thermocycling conditions were as follows (30 cycles): denaturation at 95°C for s, annealing at 55°C for 1 min and extension at 72'C for 1 min. Primer sequences (F=forward; R=reverse) used were: 5'-CGC TCT GTC ACC TGT TGT ACT C- 3' 5'-CGT GAT GAA GCT GAT GTA CTC Approximate PCR product length was 620 bp.
Results Following experiments to show increased regeneration capacity and improvement of maize transformation frequencies by expression of maize LEC1, the polynucleotide was then introduced into wheat scutellar and inflorescence explants, driven by the maize In2 promoter. Both tissues are used for wheat transformation.
Subsequent to the induction of somatic embryos from both tissues after three weeks on a 2,4-D-containing induction medium, calluses were assessed prior to transfer onto shoot regeneration medium. Callus assessment involved: a) scoring calluses as 0 non-embryogenic callus, 1 25%, 2 25-50%, 3 4 75-100% of callus surface embryogenic, and b) determining embryogenic capacity expressed in percentage as the number of embryogenic calluses total number of calluses (scutella or inflorescence) assessed.
Scutellum calluses Mean callus scores of control (1.4 0.3) and LEC-bombarded (1.4 0.3) scutellar tissues of wheat line NH535 were not significantly different. However,
I
I
callus score of LEC-bombarded scutella (1.5 0.5) of wheat line BO 014 was significantly improved in comparison with the control (0.5 Similarly, embryogenic capacity of line NH535 did not seem to be affected by LEC treatment (LEC calluses 84.3 control calluses However, LECbombarded line BO 014 had clear increases in the embryogenicMallisfrequency (LEC calluses 75.4 16.8%, control calluses 36.7 Examining the quality of embryogenic calluses formed, both lines showed significant increases in the number of 'good' calluses produced i.e. calluses with scores of 3 or 4. 'Good' quality callus of line NH535 increased from 5 to 22.3 whilst line BO 014 increased from 0 to 23.6%. These calluses were generally large, rapidly growing and vigorous.
After callus induction and assessment, calluses were transferred onto shoot induction media for a total of six weeks. Shoot regeneration of calluses was determined, as the number of shoot regenerating calluses I total number of calluses assessed (expressed as percentages). Shoot regeneration of cultures corresponded with the quality and quantity of somatic embryos produced in each callus. Hence, regeneration of LEC-bombarded (71.9 12.1) and control (70 14) callus tissues of line NH535 were not significantly different. However, regeneration of LEC-bombarded calluses (52.3 26.9) of wheat line BO 014 was significantly improved in comparison with the control (15.6 6.3).
To test the suitability of LEC as a positive selection system for wheat, sample tissues from vigorous calluses were analyzed for the presence of LEC sequences. Forty-one BO 014 and 13 NH535 calluses were selected. The results were that 10/41 BO 014 calluses and 8/13 NH535 were PCR positive.
Thus, transformed lines were identified without selection at frequencies of 24.4% and 61.5%. These frequencies are comparable with conventional selection systems such as herbicide- and antibiotic-resistance systems bar, nptll) applied in wheat transformation where selection 'escape' frequencies are commonly high and variable. Furthermore, we know of no other report of wheat transformation by morphological selection in the absence of a selection agent.
Callus transformation frequencies were 5.6% and 4.4% in NH535 and BO 014 lines, respectively. Transgenic plants were also recovered from LEC-positive callus lines. Seven non-clonal plants were recovered from NH535 and six nonclonal plants were recovered from B0 014 to give plant transformation frequencies of 3.9 and respectively, based on the number of explants bombarded.
Inflorescence calluses The use of inflorescence tissues as explants for the tissue culture and transformation of wheat offer several advantages over seed explants such as scutella (Rasco-Gaunt and Barce 10, 1999). However 1 responses of these tissues to culture are highly genotype-dependent and calluses are often non-regenerative despite having a 'highly-embryogenic' appearance. Hence, LEC was introduced into inflorescence tissues to see whether regeneration could be enhanced on a poorly regenerating l ine such BO 0 14.
Using line 80 014, shoot regeneration was significantly improved in LECbombarded tissues, although callus quality appeared similar in bombarded and control tissues. Whereas no shoot was regenerated from control cultures, eight plants were regenerated from LEC-bombarded calluses to give a shoot regeneration frequency of 10.7%.
Tables Summary of tissue culture data Wheat Treatment Mean Embryo. Good Regeneration line callus Capacity calluses score (score a NH 535 Control 1.4 ±0.3 90.0 5 70 ±14 LECI 1.4 ±0.3 84.3 ±9.3 22.3 71.9 ±12.1 BO 014 Control 0.5 0.2 36.7 4.7 0 15.6 6.3 LECI 1.5 0.5 75.4 23.6 52.3 26.9 16.8 1
II
-62- Type of callus produced per treatment per line Callus Score NH535 B0014 Control LEC1 Control LEC1 0 10 15.7 63.2 1 45 43.3 26.3 2 40 28.7 10.5 21.4 3 5 11.2 0 17.9 4 0 1.1 0 5.7 Transformation Frequency Wheat line Callus line Plant line (non-clonal) NH 535 10/180 7/180 BO 014 8/180 6/180 EXAMPLE Expression of Chimeric Genes in Dicot Cells The LEC1 polynucleotide can also be used to improve the transformation of soybean. To demonstrate this the construct consisting of the In2 promoter and LECI coding region were introduced into embryogenic suspension cultures of soybean by particle bombardment using essentially the methods described in Parrott, L.M. Hoffman, D.F. Hildebrand, E.G. Williams, and G.B. Collins, (1989) Recovery of primary transformants of soybean, Plant Cell Rep. 7:615-617.
This method with modifications is described below.
Seed was removed from pods when the cotyledons were between 3 and mm in length. The seeds were sterilized in a Chlorox solution for minutes after which time the seeds were rinsed with sterile distilled water. The immature cotyledons were excised by first cutting away the portion of the seed that contains the embryo axis. The cotyledons were then removed from the seed coat by gently pushing the distal end of the seed with the blunt end of the scalpel blade. The cotyledons were then placed (flat side up) SB1 initiation medium (MS salts, B5 vitamins, 20 mg/L 2,4-D, 31.5 g/I sucrose, 8 g/L TC Agar, pH The Petri plates were incubated in the light (16 hr day; 75-80 ipE) at 26" C. After 4 I -63weeks of incubation the cotyledons were transferred to fresh SB1 medium. After an additional two weeks, globular stage somatic embryos that exhibit proliferative areas were excised and transferred to FN Lite liquid medium (Samoylov, V.M., D.M. Tucker, and W.A. Parrott (1998) Soybean [Glycine max Merrilll embryogenic cultures: the role of sucrose and total nitrogen content on proliferation. In Vitro Cell Dev. Biol.- Plant 34:8-13). About 10 to 12 small clusters of somatic embryos were placed in 250 ml flasks containing 35 ml of SB172 medium. The soybean embryogenic suspension cultures were maintained in mL liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights (20 gE) on a 16:8 hour day/night schedule. Cultures were sub-cultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.
Soybean embryogenic suspension cultures were then be transformed using particle gun bombardment (Klein et al. (1987) Nature (London) 327:70, U.S.
Patent No. 4,945,050). A BioRad Biolistic M PDS1000/HE instrument was used for these transformations. A selectable marker gene which was used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) Nature 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from E. coli; Gritz et al. (1983) Gene 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of Agrobacterium tumefaciens.
To 50 gL of a 60 mg/mL 1 pm gold particle suspension was added (in order): RL DNA (1 pg/p.L), 20 pl spermidine (0.1 and 50 pL CaCI 2 (2.5 The particle preparation was agitated for three minutes, spun in a microfuge for seconds and the supernatant removed. The DNA-coated particles were washed once in 400 IL 70% ethanol and resuspended in 40 pL of anhydrous ethanol.
The DNA/particle suspension was sonicated three times for one second each.
Five pL of the DNA-coated gold particles were then loaded on each macro carrier disk.
Approximately 300-400 mg of a two-week-old suspension culture was placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. Membrane rupture pressure was set at 1100 psi and the chamber was evacuated to a vacuum of 28 inches mercury. The tissue was placed approximately 8 cm away from the retaining screen, and was bombarded three
I
-64times. Following bombardment, the tissue was divided in half and placed back into 35 ml of FN Lite medium.
Five to seven days after bombardment, the liquid medium was exchanged with fresh medium. Eleven days post bombardment the medium was exchanged with fresh medium containing 50 mg/mL hygromycin. This selective medium was refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue was observed growing from untransformed, necrotic embryogenic clusters.
Isolated green tissue was removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line was treated as an independent transformation event.
These suspensions were then subcultured and maintained as clusters of immature embryos, or tissue was regenerated into whole plants by maturation and germination of individual embryos.
Two different genotypes were used in these experiments: 92B91 and 93882. Samples of tissue were either bombarded with the hygromycin resistance gene alone or with a 1:1 mixture of the hygromycin resistance gene and the LEC 1 construct. Embryogenic cultures generated from 92B91 generally produce transformation events while cultures from 93882 are much more difficult to transform. For transformation experiments with 92B91, approximately equal numbers of transformants were recovered from bombardments conducted with the LEC1 polynucleotide as without it. Twenty-nine transformants were recovered from the LECl-treated 92B91 tissue while 27 transformants were recovered from tissue receiving only the hygromycin resistance gene. In contrast, transformants were only recovered from 93882 tissue receiving the LEC1 polynucleotide (none were recovered from the treatment using only the hygromycin resistance gene).
Five transformants were recovered from 93B82 tissue bombarded with the LEC1 polynucleotide while no transformants were recovered from tissue treated with only the hygromycin resistance gene. These results show that the LEC1 polynucleotide will be very valuable for gene transfer to recalcitrant genotypes of soybean.
Claims (58)
1. An isolated Led nucleic acid comprising a member selected from the group consisting of: a polynucleotide which encodes a polypeptide of SEQ ID NO:22; a polynucleotide having at least 75% sequence identity to SEQ ID NO:21, wherein the sequence identity is based on the entire sequence and is determined by GAP analysis using Gap Weight of 50 and Length Weight of 3; a polynucleotide having the sequence set forth in SEQ ID NO:21; and a polynucleotide complementary to a polynucleotide of through
2. A vector comprising at least one nucleic acid of claim 1.
3. An expression cassette comprising at least one nucleic acid of claim 1 operably linked to a promoter, wherein the nucleic acid is in sense or antisense orientation.
4. The expression cassette of claim 3, wherein the nucleic acid is operably linked in antisense orientation to the promoter. A plant cell containing at least one isolated nucleic acid of claim 1.
6. A transgenic plant comprising at least one expression cassette of claim 3.
7. The transgenic plant of claim 9, wherein the plant is corn, soybean, sorghum, wheat, rice, alfalfa, sunflower, canola or cotton.
8. Seed from the transgenic plant of claim 6.
9. The seed from the transgenic plant of claim 7. A Led isolated protein comprising a member selected from the group consisting of: a polypeptide comprising at least 75% sequence identity to SEQ ID NO:22, wherein the sequence identity is determined by GAP analysis using Gap Weight of 12 and Length Weight of 4; a polypeptide encoded by a nucleic acid of claim 1; a polypeptide encoded by a nucleic acid of SEQ ID NO:21; and a polypeptide having the sequence set forth in SEQ ID NO:22.
11. The protein of claim 10, wherein the LEC1 protein is from wheat.
12. A ribonucleic acid sequence encoding a protein of claim
13. A method for modulating LEC1 activity in a plant, comprising: transforming a plant cell with at least one expression cassette of claim 3 and [R:\LIBFF]07185.doc:ANB 0 regenerating a transformed plant that expresses the at least one nucleic acid in an amount sufficient to modulate LEC1 activity in the plant. D 14. The method of claim 13, wherein the plant is corn, soybean, sorghum, wheat, Srice, alfalfa, sunflower, canola or cotton. c 5 15. The method of claim 13, wherein LEC1 activity is increased.
16. The method of claim 13, wherein LEC1 activity is decreased. S17. A method for transiently modulating the level of LEC1 activity in plant cells O comprising introducing at least one nucleic acid of claim 1. N 18. The method of claim 17 wherein the at least one nucleic acid is a ribonucleic acid. c
19. A method for transiently modulating the level of LEC1 activity in plant cells comprising introducing at least one polypeptide of claim A method for enhancing tissue culture response in a plant cell comprising introducing into the plant cell at least one LEC1 polypeptide or at least one LEC1 polynucleotide under conditions sufficient to enhance tissue culture response.
21. The method of claim 20 wherein the plant cell is transformed with at least one LEC1 polynucleotide.
22. The method of claim 20 wherein at least one polynucleotide is operably linked to a promoter driving expression in the plant cell and growing the plant cell.
23. The method of claim 20 wherein the plant cell is a recalcitrant cell.
24. The method of claim 23 wherein the plant cell is an inbred maize cell. A method for inducing somatic embryogenesis in a plant cell comprising introducing into a responsive plant cell at least one LEC1 polypeptide or at least one LEC1 polynucleotide, wherein the responsive plant cell is transformed and grown under conditions sufficient to stimulate the production of a transformed embryo and wherein the plant cell is other than an Arabidopsis cell.
26. The method of claim 25 wherein the plant cell is transformed with at least one LEC1 polynucleotide.
27. The method of claim 26 wherein at least one polynucleotide is operably linked to a promoter driving expression in the plant cell.
28. The method of claim 25 further comprising growing the transformed embryo under plant growing conditions to produce a regenerated plant.
29. The method of claim 25 wherein the plant cell is from corn, soybean, sorghum, wheat, rice, alfalfa, sunflower, canola or cotton. [R:\LIBFF]07185.doc:ANB A plant produced by the method of any one of claims 25-29.
31. A method for positive selection of a transformed cell comprising introducing into a responsive plant cell at least one LEC1 polynucleotide or at least one LEC1 polypeptide and growing the transformed plant cell, wherein the responsive plant cell is transformed and grown under conditions sufficient to induce embryogenesis to provide a positive selection means.
32. The method of claim 31 wherein the plant cell is transformed with at least one polynucleotide.
33. The method of claim 32 wherein at least one polynucleotide is operably o0 linked to a promoter driving expression in a plant.
34. The method of claim 31 further comprising altering media components to favor the growth of transformed plant cells. The method of claim 34 wherein the media components are altered to reduce somatic embryogenesis in non-transformed cells.
36. The method of claim 32 wherein the at least one polynucleotide is excised.
37. The method of claim 36 wherein the polynucleotide is flanked by FRT sequences to allow FLP mediated excision of the polynucleotide.
38. A method for inducing apomixis in a plant cell comprising introducing into a responsive plant cell at least one LEC1 polypeptide or at least one LEC1 polynucleotide and growing the plant cell, wherein the introducing and growing is done under conditions sufficient to produce a transformed somatic embryo.
39. The method of claim 38 wherein the plant cell is transformed with at least one LEC1 polynucleotide. The method of claim 39 wherein the at least one polynucleotide is operably linked to a promoter driving expression in a plant cell
41. The method of claim 38 further comprising suppressing in the plant cell the expression of an FIE polycomb polynucleotide using sense or antisense methods.
42. The method of claim 38 further comprising growing the embryo under plant growing conditions to produce a regenerated plant.
43. The method of claim 40 wherein the promoter is an inducible promoter.
44. The method of claim 40 wherein the at least one polynucleotide is expressed in integument or nucellus tissue. A plant produced by the method of any one of claims 38-44.
46. The plant of claim 45, wherein the plant is male sterile. [R:\LIBFF]07185.doc:ANB
47. A method for increasing transformation efficiency comprising introducing at least one LEC1 polypeptide or at least one LEC1 polynucleotide into a responsive plant cell under conditions sufficient to increase transformation efficiency.
48. The method of claim 47 wherein the transformation is conducted in medium that retards growth of somatic embryo growth in non-transformed plants.
49. The method of claim 48 wherein transformation is conducted with reduced levels of auxin or no auxin. The method of claim 47 wherein the plant cell is transformed with at least one LEC1 polynucleotide.
51. The method of claim 50 wherein the at least one polynucleotide is operably linked to a promoter driving expression in a plant cell
52. The method of claim 47 wherein the plant cell is a recalcitrant cell.
53. The method of claim 52 wherein the plant cell is an inbred maize cell.
54. A method for increasing recovery of regenerated plants comprising introducing into a responsive plant cell at least one LEC1 polypeptide or at least one LEC1 polynucleotide and growing the plant cell, wherein the introducing and growing are under conditions sufficient to produce a regenerated plant. The method of claim 54 wherein the plant cell is transformed with at least one LEC1 polynucleotide.
56. The method of claim 55 wherein the at least one polynucleotide is operably linked to a promoter driving expression in a plant cell
57. The method of claim 55 wherein the plant cell is a recalcitrant cell.
58. The method of claim 57 wherein the plant cell is an inbred maize cell.
59. Transgenic seed of the plant of claim 30 or
60. The isolated Led nucleic acid of claim 1, substantially as hereinbefore described with reference to any one of the examples.
61. A vector comprising at least one nucleic acid of claim
62. An expression cassette comprising at least one nucleic acid of claim operably linked to a promoter, wherein the nucleic acid is in sense or antisense orientation.
63. A plant cell containing at least one isolated nucleic acid of claim
64. A transgenic plant comprising at least one expression cassette of claim 62. Seed from the transgenic plant of claim 64. [R:\LIBFF]07185.doc:ANB
66. An isolated Led of claim 10, substantially as hereinbefore described with reference to any one of the examples.
67. A ribonucleic acid sequence encoding a protein of claim 66.
68. The method of claim 13, substantially as hereinbefore described with reference to any one of the examples.
69. The method of claim 20, substantially as hereinbefore described with reference to any one of the examples. A method for inducing somatic embryogenesis in a plant cell comprising introducing into a responsive plant cell at least one LEC1 polypeptide or at least one LEC1 polynucleotide, substantially as hereinbefore described with reference to any one of the examples.
71. A method for positive selection of a transformed cell comprising introducing into a responsive plant cell at least one LEC1 polynucleotide or at least one LEC1 polypeptide and growing the transformed plant cell, substantially as hereinbefore described with reference to any one of the examples.
72. A method for inducing apomixis in a plant cell comprising introducing into a responsive plant cell at least one LEC1 polypeptide or at least one LEC1 polynucleotide and growing the plant cell, substantially as hereinbefore described with reference to any one of the examples.
73. The method of claim 47, substantially as hereinbefore described with reference to any one of the examples.
74. A method for increasing recovery of regenerated plants comprising introducing into a responsive plant cell at least one LEC1 polypeptide or at least one LEC1 polynucleotide and growing the plant cell, substantially as hereinbefore described with reference to any one of the examples. Dated 29 September, 2005 E.I. Du Pont De Nemours Co. Pioneer Hi-Bred International, Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON [R:\LIBFF]07185.doc:ANB
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003200679A AU2003200679B2 (en) | 1998-11-09 | 2003-02-26 | Transcriptional Activator LEC1 Nucleic Acids, Polypeptides and Their Use |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/107643 | 1998-11-09 | ||
| US60/107810 | 1998-11-10 | ||
| AU14741/00A AU768243B2 (en) | 1998-11-09 | 1999-11-09 | Transcriptional activator LEC1 nucleic acids, polypeptides and their uses |
| AU2003200679A AU2003200679B2 (en) | 1998-11-09 | 2003-02-26 | Transcriptional Activator LEC1 Nucleic Acids, Polypeptides and Their Use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU14741/00A Division AU768243B2 (en) | 1998-11-09 | 1999-11-09 | Transcriptional activator LEC1 nucleic acids, polypeptides and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003200679A1 AU2003200679A1 (en) | 2003-05-01 |
| AU2003200679B2 true AU2003200679B2 (en) | 2005-11-17 |
Family
ID=39367680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003200679A Ceased AU2003200679B2 (en) | 1998-11-09 | 2003-02-26 | Transcriptional Activator LEC1 Nucleic Acids, Polypeptides and Their Use |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2003200679B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118620950A (en) * | 2024-08-13 | 2024-09-10 | 浙江大学海南研究院 | Preparation method based on application of OsLEC1 gene in rice callus differentiation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003001902A2 (en) * | 2001-06-29 | 2003-01-09 | E. I. Du Pont De Nemours And Company | Alteration of oil traits in plants |
-
2003
- 2003-02-26 AU AU2003200679A patent/AU2003200679B2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003001902A2 (en) * | 2001-06-29 | 2003-01-09 | E. I. Du Pont De Nemours And Company | Alteration of oil traits in plants |
| WO2003002751A2 (en) * | 2001-06-29 | 2003-01-09 | E. I. Du Pont De Nemours And Company | Alteration of oil traits in plants |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118620950A (en) * | 2024-08-13 | 2024-09-10 | 浙江大学海南研究院 | Preparation method based on application of OsLEC1 gene in rice callus differentiation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU768243B2 (en) | Transcriptional activator LEC1 nucleic acids, polypeptides and their uses | |
| US6825397B1 (en) | LEC1 trancriptional activator nucleic acids and methods of use thereof | |
| US20080060099A1 (en) | Cell Cycle Nucleic Acids, Polypeptides and Uses Thereof | |
| US7268271B2 (en) | Methods of use of LEC1 polynucleotides and polypeptides | |
| AU747844B2 (en) | Methods of using viral replicase polynucleotides and polypeptides | |
| EP1356064B1 (en) | Transcriptional regulator nucleic acids, polypeptides and methods of use thereof | |
| US20030167526A1 (en) | Compositions and methods for identifying transformed cells | |
| AU2002225890A1 (en) | Transcriptional regulator nucleic acids, polypeptides and methods of use thereof | |
| AU2003200679B2 (en) | Transcriptional Activator LEC1 Nucleic Acids, Polypeptides and Their Use | |
| AU2002245646B2 (en) | Cell cycle nucleic acids, polypeptides and uses thereof | |
| US20080109925A1 (en) | Transcriptional Regulatory Nucleic Acids, Polypeptides and Methods of Use Thereof | |
| AU2002245646A1 (en) | Cell cycle nucleic acids, polypeptides and uses thereof | |
| AU2001297744A1 (en) | Cell cycle nucleic acids, polypeptides and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |